前往化源商城

531-75-9 靶点实验数据

HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:24565 靶标:N/A
External ID: ERK5 transcriptional activity-HTS
Protocol: Stable cells plated on a 384-well plate (2500 cells/well) were treated with test compounds at the concentration of 5 muM for 18 hrs. The level of luciferase activity was assayed using a
Luciferase kit (Promega corporation, Madison, WI) and a series of positive and negative control compounds were used as references.
Comment:
Luciferase activity (AU)
104
108
64
28
100
152
176
52
124
44
60
60
32
96
60
144
28
64
84
44
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: CYP3A4437
Protocol: Assay Protocol Summary:

Two ul of enzyme-substrate mix was dispensed into medium binding white/solid 1536-well plates (Greiner Bio-One North America Inc., Monroe, NC) using a Flying Reagent Dispenser (FRD, Aurora Discovery, San Diego, CA). Test compounds dissolved in DMSO and positive control (ketoconazole) were transferred to the assay plates at 23 nl using a Pintool station (Wako, San Diego, CA). The assay plates were incubated at room temperature for 10 min. Then 2 ul of NADPH regeneration solution was added to each well of the assay plates using an FRD and incubated at room temperature for 1 h. The reaction was stopped by adding 4 ul of detection reagent using an FRD and after 20 min incubation at room temperature, the luminescence signal was measured using a ViewLux plate reader (Perkin Elmer, Shelton, CT). Data were expressed as relative luminescence units.
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000073560 uM-Replicate_1Activity at 0.0000367800 uM-Replicate_1Activity at 0.0000735600 uM-Replicate_1Activity at 0.0001677464 uM-Replicate_1Activity at 0.0003678000 uM-Replicate_1Activity at 0.0007362988 uM-Replicate_1Activity at 0.00153 uM-Replicate_1Activity at 0.00368 uM-Replicate_1Activity at 0.00723 uM-Replicate_1Activity at 0.00914 uM-Replicate_1Activity at 0.018 uM-Replicate_1Activity at 0.039 uM-Replicate_1Activity at 0.092 uM-Replicate_1Activity at 0.191 uM-Replicate_1Activity at 0.460 uM-Replicate_1Activity at 0.910 uM-Replicate_1Activity at 1.182 uM-Replicate_1Activity at 2.302 uM-Replicate_1Activity at 4.834 uM-Replicate_1Activity at 11.49 uM-Replicate_1Activity at 23.94 uM-Replicate_1Activity at 57.45 uM-Replicate_1Activity at 115.4 uM-Replicate_1Activity at 193.5 uM-Replicate_1Activity at 288.3 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2Fit_InfiniteActivity-Replicate_2
Inactive0-8.32134.95490.64234-4.834640 0 0 0 0 0 1-4.4443-2.77887.36895.36932.33973.33831.6715-4.4443QC'd by Sytravon0
Inhibitor2.391969.704984Complete curve; high efficacy-5.62130.90.993-69.49290.212-1.10 0 0 0 0 0 0-66.6604-0.25131.2197-5.3806-9.9311-37.162-53.3921-66.6604QC'd by Sytravon0
Inhibitor9.522176.407442Partial curve; high efficacy-5.02131.1110.9951-75.90940.498-2.10 0 0 0 0 0 0-66.59123.4283-1.6815-1.5622-0.1199-13.7121-41.7015-66.5912QC'd by Sytravon0
Inactive0-4.52131.75290.9212-24.98775.540 0 0 0 0 0 0-17.48977.36232.46169.84163.36053.96510.8896-17.4897QC'd by Sytravon0
Inhibitor1.5092115.26487Complete curve; high efficacy-5.82131.46410.9934-109.85685.4073-1.10 0 0 0 0 0 0-110.2979-0.81499.86343.518-7.3368-73.6123-100.848-110.2979QC'd by Sytravon0
Inhibitor1.6933117.978187Complete curve; high efficacy-5.77134.50450.9912-112.735.2481-1.10 0 0 0 0 0 0-115.265815.93722.4103-1.24092.2518-88.9575-109.7932-115.2658QC'd by Sytravon0
Inhibitor4.772481.295643Partial curve; high efficacy-5.321310.9946-78.60572.6899-2.10 0 0 0 0 0 0-71.671-0.64476.43020.1885-3.4582-24.3313-55.7062-71.671QC'd by Sytravon0
Inhibitor7.563794.395183Complete curve; high efficacy-5.12134.95490.9967-94.6258-0.2307-1.10 0 0 0 0 0 0-93.87483.4317-2.5012-1.7201-2.44552.6182-85.3984-93.8748QC'd by Sytravon0
Inhibitor2.683765.029784Complete curve; high efficacy-5.57134.0950.989-65.3833-0.3537-1.10 0 0 0 0 0 0-70.4739-2.312-0.8042-1.22813.0628-22.6396-60.696-70.4739QC'd by Sytravon0
Inhibitor7.563757.206142Partial curve; partial efficacy-5.12131.62590.9942-54.13193.0742-2.20 0 0 0 0 0 0-52.30876.2072.82521.47620.0987-3.9796-35.0702-52.3087QC'd by Sytravon0
Inhibitor1.198874.619785Complete curve; high efficacy-5.92131.13410.9933-70.92043.6993-1.10 0 0 0 0 0 0-71.49064.2219-0.18864.5237-17.1469-46.9199-63.4145-71.4906QC'd by Sytravon0
Inhibitor2.1317118.451686Complete curve; high efficacy-5.67132.72020.993-110.08868.3631-1.10 0 0 0 0 0 0-116.12727.57825.10285.881412.5352-56.6231-102.2879-116.1272QC'd by Sytravon0
Inhibitor2.1317122.703187Complete curve; high efficacy-5.67132.40640.9787-115.72726.9759-1.10 0 0 0 0 0 0-122.07513.858917.443-6.083311.7009-62.2871-106.7609-122.0751QC'd by Sytravon0
Inhibitor6.7412121.082984Complete curve; high efficacy-5.17134.0950.9954-126.4671-5.3842-1.10 0 0 0 0 0 0-126.975-0.8069-3.4445-2.4548-11.8834-10.2564-113.7668-126.975QC'd by Sytravon0
Inhibitor4.772486.82744Partial curve; high efficacy-5.321310.9941-85.3831.444-2.10 0 0 0 0 0 0-78.6992-2.43161.8612-0.004-1.8987-28.5107-58.6303-78.6992QC'd by Sytravon0
Inhibitor7.5637125.15484Complete curve; high efficacy-5.12133.92950.9979-122.58722.5668-1.10 0 0 0 0 0 0-123.07953.09863.12671.8871-2.10935.2605-101.0355-123.0795QC'd by Sytravon0
Inhibitor0.6741119.919989Complete curve; high efficacy-6.17131.37230.9986-109.745410.1745-1.10 0 0 0 0 0 0-110.8548.84597.74156.7576-35.5397-88.9969-106.7803-110.854QC'd by Sytravon0
Inhibitor6.7412115.981384Complete curve; high efficacy-5.17132.30310.9963-113.59672.3846-1.10 0 0 0 0 0 0-113.37-1.2322-1.59845.85995.7708-6.0722-86.9448-113.37QC'd by Sytravon0
Inhibitor1.5092114.050988Complete curve; high efficacy-5.82131.96730.9946-113.91580.1351-1.10 0 0 0 0 0 0-113.0117-0.8223-4.0553-2.3728-1.6822-81.3904-111.2484-113.0117QC'd by Sytravon0
Inhibitor8.486660.792742Partial curve; partial efficacy-5.07132.40640.9868-57.96392.8287-2.20 0 0 0 0 0 0-56.54736.87814.87661.3348-2.20081.3516-39.1581-56.5473QC'd by Sytravon0
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: CYP2D6395
Protocol: Assay Protocol Summary:

Two ul of enzyme-substrate mix was dispensed into medium binding white/solid 1536-well plates (Greiner Bio-One North America Inc., Monroe, NC) using a Flying Reagent Dispenser (FRD, Aurora Discovery, San Diego, CA). Test compounds dissolved in DMSO and positive control (quinidine) were transferred to the assay plates at 23 nl using a Pintool station (Wako, San Diego, CA). The assay plates were incubated at room temperature for 10 min. Then 2 ul of NADPH regeneration solution was added to each well of the assay plates using an FRD and incubated at room temperature for 1 h. The reaction was stopped by adding 4 ul of detection reagent using an FRD and after 20 min incubation at room temperature, the luminescence signal was measured using a ViewLux plate reader (Perkin Elmer, Shelton, CT). Data were expressed as relative luminescence units.
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000073560 uM-Replicate_1Activity at 0.0000367800 uM-Replicate_1Activity at 0.0000735600 uM-Replicate_1Activity at 0.0001677464 uM-Replicate_1Activity at 0.0003678000 uM-Replicate_1Activity at 0.0007362988 uM-Replicate_1Activity at 0.00153 uM-Replicate_1Activity at 0.00368 uM-Replicate_1Activity at 0.00723 uM-Replicate_1Activity at 0.00914 uM-Replicate_1Activity at 0.018 uM-Replicate_1Activity at 0.039 uM-Replicate_1Activity at 0.092 uM-Replicate_1Activity at 0.191 uM-Replicate_1Activity at 0.460 uM-Replicate_1Activity at 0.910 uM-Replicate_1Activity at 1.182 uM-Replicate_1Activity at 2.302 uM-Replicate_1Activity at 4.834 uM-Replicate_1Activity at 11.49 uM-Replicate_1Activity at 23.94 uM-Replicate_1Activity at 57.45 uM-Replicate_1Activity at 115.4 uM-Replicate_1Activity at 193.5 uM-Replicate_1Activity at 288.3 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2Fit_InfiniteActivity-Replicate_2
Inactive0-7.260.70.983122040 0 0 0 0 0 0 018.72430.75090.74030.16150.22082.57129.062412.490518.7243QC'd by Labotest0
Inactive00043.08132.90954.18193.06831.54751.9993-1.48293.82823.0813QC'd by Labotest0
Inhibitor10.96462.697110Partial curve; high efficacy; poor fit-4.964.95490.998-66.9977-4.3007-2.31 0 0 0 0 0 0 0-65.7875-42.8846-3.6636-4.8429-3.3836-3.8623-4.4736-41.4229-65.7875QC'd by Microsource0
Inhibitor38.901833.850110Partial curve; partial efficacy; poor fit-4.414.95490.924-33.35010.5-2.40 0 0 0 0 0 0 0-29.0418-1.55510.52060.875-1.2476-0.5605-1.80927.4199-29.0418QC'd by SIGMA0
Inhibitor1.737781.229885Complete curve; high efficacy-5.761.96730.9976-79.95641.2734-1.10 0 0 0 0 0 0 0-78.3324.47950.76060.0181-0.701-3.7995-49.0322-80.0522-78.332QC'd by Tocris0
Inhibitor34.671337.231710Partial curve; partial efficacy; poor fit-4.462.35310.9195-37.23170-2.40 0 0 0 0 0 0 0-28.52643.96925.0423-3.0201-3.1048-1.1738-0.8348-2.4447-28.5264QC'd by Microsource0
Inhibitor15.487171.27341Partial curve; high efficacy-4.811.44870.9928-70.41130.8617-2.10 0 0 0 0 0 0 0-61.76430.28531.9381-1.2811-0.34364.6186-4.2001-27.4432-61.7643QC'd by GVK0
Inhibitor0.218891.972890Complete curve; high efficacy-6.660.80.9894-90.01021.9626-1.10 0 0 0 0 0 0 0-83.87692.77070.8657-14.6874-27.4321-55.0254-79.0233-92.6031-83.8769QC'd by Prestwick Chemical; Inc.0
Inhibitor34.671345.828810Single point of activity-4.462.35310.9938-45.82880-30 0 0 0 0 0 0 0-35.0976-0.4182-0.112-0.91482.1786-0.5211-0.77-3.3082-35.0976QC'd by Vitas0
Inhibitor13.8029116.598142Partial curve; high efficacy-4.860.70.9704-115.4741.1242-2.10 0 0 0 0 0 0 0-87.4803-1.2071.2781-1.1552-1.0641-0.761-34.877-47.6739-87.4803QC'd by Vitas0
Inhibitor19.497171.169541Partial curve; high efficacy-4.712.33320.9649-71.6292-0.4597-2.10 0 0 0 0 0 0 0-66.007-7.5073.5896-6.58233.21022.04942.4442-17.4355-66.007QC'd by Enzo0
Inactive0004-0.33970.68341.1935-3.1601-7.1353-6.692-3.5353-4.6055-0.3397QC'd by Microsource0
Inhibitor38.901899.707710Single point of activity-4.412.90230.9979-103.2475-3.5398-30 0 0 0 0 0 0 0-78.9754-2.6538-1.9475-2.4198-3.036-5.7354-4.4174-6.1242-78.9754QC'd by Labotest0
Inactive00040.55794.29663.86970.9141.57842.77632.2827-0.27460.5579QC'd by Microsource0
Inactive0004-2.28934.50485.93892.79056.12561.13645.75735.7586-2.2893QC'd by Tocris0
Inhibitor12.301842.282721Partial curve; partial efficacy-4.912.33320.9667-45.1528-2.8702-2.20 0 0 0 0 0 0 0-43.5551-8.1379-5.4062-0.92150.1464-0.2747-3.1761-22.7908-43.5551QC'd by Labotest0
Inactive00042.7074-0.37290.3242.07662.64641.1615-0.70884.47812.7074QC'd by Prestwick0
Inactive0004-1.99643.70481.65273.62083.19225.03624.9342-1.7586-1.9964QC'd by Microsource0
Inactive0-6.360.80.89615-7.047740 0 0 0 0 0 0 04.9227-4.8515-7.6164-8.7898-3.26990.29170.34185.50584.9227QC'd by VitasInactive00
Inhibitor3.4671109.162545Partial curve; high efficacy-5.460.90.9982-103.53135.6312-2.10 0 0 0 0 0 0 0-96.39795.98693.1773.47834.7559-9.3266-39.4946-74.1667-96.3979QC'd by Enzo0
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: CYP2C9536
Protocol: Assay Protocol Summary:

Two ul of enzyme-substrate mix supplemented with 0.4% Bovine Serum Albumin was dispensed into medium binding white/solid 1536-well plates (Greiner Bio-One North America Inc., Monroe, NC) using a Flying Reagent Dispenser (FRD, Aurora Discovery, San Diego, CA). Test compounds dissolved in DMSO and positive control (sulfaphenazole) were transferred to the assay plates at 23 nl using a Pintool station (Wako, San Diego, CA). The assay plates were incubated at room temperature for 10 min. Then 2 ul of NADPH regeneration solution was added to each well of the assay plates using an FRD and incubated at 37C for 1 h. The reaction was stopped by adding 4 ul of detection reagent using an FRD and after 20 min incubation at room temperature, the luminescence signal was measured using a ViewLux plate reader (Perkin Elmer, Shelton, CT). Data were expressed as relative luminescence units.
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000073560 uM-Replicate_1Activity at 0.0000367800 uM-Replicate_1Activity at 0.0000735600 uM-Replicate_1Activity at 0.0001677464 uM-Replicate_1Activity at 0.0003678000 uM-Replicate_1Activity at 0.0007362988 uM-Replicate_1Activity at 0.00153 uM-Replicate_1Activity at 0.00368 uM-Replicate_1Activity at 0.00723 uM-Replicate_1Activity at 0.00914 uM-Replicate_1Activity at 0.018 uM-Replicate_1Activity at 0.039 uM-Replicate_1Activity at 0.092 uM-Replicate_1Activity at 0.191 uM-Replicate_1Activity at 0.460 uM-Replicate_1Activity at 0.910 uM-Replicate_1Activity at 1.182 uM-Replicate_1Activity at 2.302 uM-Replicate_1Activity at 4.834 uM-Replicate_1Activity at 11.49 uM-Replicate_1Activity at 23.94 uM-Replicate_1Activity at 57.45 uM-Replicate_1Activity at 115.4 uM-Replicate_1Activity at 193.5 uM-Replicate_1Activity at 288.3 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2Fit_InfiniteActivity-Replicate_2
Inhibitor21.317485.520741Partial curve; high efficacy-4.67133.19250.957-74.520711-2.10 0 0 0 0 0 0-71.26736.65818.66165.03429.029624.68310.5948-71.2673QC'd by Microsource0
Inactive00040.31867.0625.1975.69257.23591.2670.52010.3186QC'd by Microsource0
Inhibitor7.563793.544743Partial curve; high efficacy-5.12131.92820.9984-89.27954.2653-2.10 0 0 0 0 0 0-87.52897.16565.07882.79792.1575-3.7741-60.4613-87.5289QC'd by Tocris0
Inhibitor26.83748.635610Single point of activity-4.57132.24810.9788-42.84845.7872-30 0 0 0 0 0 0-35.46775.96295.47962.709210.27554.6543-0.1967-35.4677QC'd by NCI0
Inhibitor8.4866130.766843Partial curve; high efficacy-5.071310.9992-119.896710.8701-2.10 0 0 0 0 0 0-102.475811.946611.24277.15545.0781-16.0537-65.0649-102.4758QC'd by BIOMOL0
Inhibitor5.354799.189644Partial curve; high efficacy-5.27130.90.9888-96.57122.6185-2.10 0 0 0 0 0 0-87.001-0.2592-1.6376.8143-4.5159-32.2161-61.4841-87.001QC'd by BIOMOL0
Inactive0-4.67132.33320.6923-15.1448-0.540 0 0 0 0 0 0-13.8707-3.7401-1.27785.1005-4.69041.916-3.5213-13.8707QC'd by InterBioScreen0
Inhibitor25.401256.202240Partial curve; partial efficacy-4.59514.50450.9727-57.7888-1.5865-2.20 0 0 0 0 0 0 0-57.6748-1.4876-4.4957-6.22962.86763.1906-3.7494-18.0858-57.6748QC'd by LightBiologicalsInhibitor40.258241.12110Single point of activity-4.39512.95230.943-42.7254
Inhibitor7.563797.471243Partial curve; high efficacy-5.12131.92820.9955-91.45176.0195-2.10 0 0 0 0 0 0-89.13426.42811.19024.98681.8065-2.3315-62.2028-89.1342QC'd by Tocris0
Inhibitor21.317476.663841Partial curve; partial efficacy-4.67131.24750.9713-70.16386.5-2.20 0 0 0 0 0 0-53.059711.862810.1962-0.30794.2931.9517-17.9254-53.0597QC'd by SigmaAldrich0
Inhibitor26.837101.665640Partial curve; high efficacy-4.57131.59360.9916-96.27045.3952-2.10 0 0 0 0 0 0-73.31095.62388.78586.24482.4666-0.9326-13.5438-73.3109QC'd by Tocris0
Inhibitor3.790887.146544Partial curve; high efficacy-5.42130.80.9942-85.19521.9512-2.10 0 0 0 0 0 0-78.88451.4625-1.87161.6032-10.9203-35.4628-58.552-78.8845QC'd by Tocris0
Inhibitor37.9083129.914810Single point of activity-4.42134.95490.9896-129.29750.6173-30 0 0 0 0 0 0-114.6255-1.4437-2.5082-0.90198.8381-4.54583.1106-114.6255QC'd by SigmaAldrich0
Inhibitor26.837109.062140Partial curve; high efficacy-4.57131.34370.9459-109.3538-0.2917-2.10 0 0 0 0 0 0-82.84382.53255.07320.78280.5149-19.3744-20.4297-82.8438QC'd by Bosche0
Inactive0-4.412.90230.8395-17.3952-0.540 0 0 0 0 0 0 0-13.246-3.84691.9539-0.2562-2.65371.4770.7446-0.9487-13.246QC'd by ACC0
Inactive0-8.363.1320.36283-4.516440 0 0 0 0 0 0 02.109-4.1803-1.83775.2557-1.05048.3001-3.10856.7452.109QC'd by Pharmaron0
Inactive00040.5041-8.57852.70450.1138-10.58420.93582.08840.5041QC'd by Toronto Research0
Inhibitor44.493235.276510Single point of activity-4.35173.67720.8478-34.72730.5492-30 0 0 0 0 0 0 0-32.3137-1.4989-3.7044-1.139-0.492412.1946-1.1884-3.139-32.3137QC'd by RTI0
Inactive00046.63087.63316.0247.39860.22633.18743.42856.6308QC'd by Tocris0
Inactive00045.326112.576410.112211.536311.2627.1953.95915.3261QC'd by NCGCChem0
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Amine oxidase [flavin-containing] A
External ID: CHEMBL734043
Protocol: N/A
Comment: Journal: J. Med. Chem.
Year: 2000
Volume: 43
Issue: 25
First Page: 4747
Last Page: 4758
DOI: 10.1021/jm001028o

Target ChEMBL ID: CHEMBL3358
ChEMBL Target Name: Monoamine oxidase A
ChEMBL Target Type: SINGLE PROTEIN - Target is a single protein chain
Relationship Type: H - Homologous protein target assigned
Confidence: Homologous single protein target assigned
Standard TypeStandard RelationStandard ValueStandard Units
Inhibition=9%
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Taste receptor type 2 member 16
External ID: CHEMBL4419133
Protocol: N/A
Comment: Target ChEMBL ID: CHEMBL3309106
ChEMBL Target Name: Taste receptor type 2 member 16
ChEMBL Target Type: SINGLE PROTEIN - Target is a single protein chain
Relationship Type: D - Direct protein target assigned
Confidence: Direct single protein target assigned

Data Source: SureChEMBL Patent Bioactivity Data
PubChem Standard ValueStandard TypeStandard RelationStandard ValueStandard Units
70Activity=0.07mM
2300Activity=2.3mM
4000Activity=4mM
1000Activity=1mM
300Activity=0.3mM
70Activity=0.07mM
300Activity=0.3mM
1000Activity=1mM
400Activity=0.4mM
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Taste receptor type 2 member 16
External ID: CHEMBL4419134
Protocol: N/A
Comment: Target ChEMBL ID: CHEMBL3309106
ChEMBL Target Name: Taste receptor type 2 member 16
ChEMBL Target Type: SINGLE PROTEIN - Target is a single protein chain
Relationship Type: D - Direct protein target assigned
Confidence: Direct single protein target assigned

Data Source: SureChEMBL Patent Bioactivity Data
PubChem Standard ValueStandard TypeStandard RelationStandard ValueStandard UnitsActivity CommentData Validity Comment
1400EC50=1400000nMOutside typical range
20000EC50=20000000nMOutside typical range
EC50Not Determined
EC50Not Determined
2300EC50=2300000nMOutside typical range
1100EC50=1100000nMOutside typical range
EC50Not Determined
EC50Not Determined
1000EC50=1000000nMOutside typical range
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:Center for Chemical Genomics, University of Michigan 靶标:N/A
External ID: TargetID_659_CEMA
Protocol: Black, standard capacity streptavidin-coated 384-well plates (Pierce 15407) were first washed with 50 L of phosphate buffer (100 mM, pH 7.0; PB7) three times using a Biotek 405 ELX plate washer. Subsequently, 5 L of biotinylated pre-miRNA substrate (500 nM final) was dispensed into the plate using a Multidrop Combi Reagent Dispenser (Thermo Scientific). Plates were then centrifuged for 1 min at 1,000 RPM (223 g), sealed with plate tape, and incubated overnight at 4 C. The following morning, plates were washed three times with 50 L of PB7, followed by the addition of 5 L of Dicer digest buffer (20 mM Tris, 12 mM NaCl, 2.5 mM MgCl2, 1 mM fresh DTT, and 4.5% DMSO) and centrifugation. Compounds (50 nL of 5 mM DMSO stock, 25 M final) were then added into the sample wells using a Sciclone (Caliper) liquid handler with V&P pintool; the same volume of DMSO was added to the control wells. The plates were incubated at 25 C for 15 min before addition of 5 L of digest buffer containing 217 g/nL Dicer (108 g/mL Dicer, 5% glycerol and 0.01% Triton X-100 final, excess with respect to pre-miRNA). For the positive control wells, digest buffer without Dicer was added. The plates were centrifuged again and resealed before being placed in a 37 C incubator for 5 h. After Dicer cleavage, plates were washed three times with 50 L of PB7. mTet-HRP in PB7 (10 L, 750 nM final) was then dispensed into each well. The plates were subsequently centrifuged, sealed, and incubated at 25 C for 2 h. Plates were then washed three times with 50 L of wash buffer (2 mM imidazole, 260 mM NaCl, 0.5 mM EDTA, 0.1% Tween-20, pH 7.0), followed by washing three additional times with 50 L of PB7. Finally, SuperSignal West Pico (25 L; Pierce) was added, the plates were incubated at 25 C for 5 min, and chemiluminescence signal was detected using a PHERAstar plate reader using LUM plus module (BMG Labtech).
Comment: The activity outcome is based on a Z-score (number of standard deviations from the negative control mean) of 3 or higher on at least 50% times that the sample was screened.

For instance, if the sample was screened in n=4 runs, it would be considered active only if it had a Z-score of 3 or above in at least 2 runs.
Z_SCORE
2.91
-0.56
0.61
2.15
0.54
-0.32
1.12
-0.07
0.61
1.55
-0.77
-0.76
-2.08
0.67
-0.35
0.17
-1.42
-0.64
-5.35
1.42
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Taste receptor type 2 member 16
External ID: CHEMBL4419124
Protocol: N/A
Comment: Target ChEMBL ID: CHEMBL3309106
ChEMBL Target Name: Taste receptor type 2 member 16
ChEMBL Target Type: SINGLE PROTEIN - Target is a single protein chain
Relationship Type: D - Direct protein target assigned
Confidence: Direct single protein target assigned

Data Source: SureChEMBL Patent Bioactivity Data
PubChem Standard ValueStandard TypeStandard RelationStandard ValueStandard Units
2300Activity=2.3mM
4000Activity=4mM
300Activity=0.3mM
70Activity=0.07mM
1500Activity=1.5mM
400Activity=0.4mM
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Homo sapiens
External ID: CHEMBL4419125
Protocol: N/A
Comment: Target ChEMBL ID: CHEMBL372
ChEMBL Target Name: Homo sapiens
ChEMBL Target Type: ORGANISM - Target is a complete organism
Relationship Type: N - Non-molecular target assigned
Confidence: Target assigned is non-molecular

Data Source: SureChEMBL Patent Bioactivity Data
PubChem Standard ValueStandard TypeStandard RelationStandard ValueStandard UnitsActivity Comment
ActivityNot Determined
4000Activity=4mM
400Activity=0.4mM
9000Activity=9mM
100Activity=0.1mM
ActivityNot Determined
40000Activity=40mM
200Activity=0.2mM
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Taste receptor type 2 member 16
External ID: CHEMBL4419126
Protocol: N/A
Comment: Target ChEMBL ID: CHEMBL3309106
ChEMBL Target Name: Taste receptor type 2 member 16
ChEMBL Target Type: SINGLE PROTEIN - Target is a single protein chain
Relationship Type: D - Direct protein target assigned
Confidence: Direct single protein target assigned

Data Source: SureChEMBL Patent Bioactivity Data
PubChem Standard ValueStandard TypeStandard RelationStandard ValueStandard UnitsActivity CommentData Validity Comment
20000EC50=20000000nMOutside typical range
EC50Not Determined
2300EC50=2300000nMOutside typical range
1100EC50=1100000nMOutside typical range
EC50Not Determined
1000EC50=1000000nMOutside typical range
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Homo sapiens
External ID: CHEMBL4419127
Protocol: N/A
Comment: Target ChEMBL ID: CHEMBL372
ChEMBL Target Name: Homo sapiens
ChEMBL Target Type: ORGANISM - Target is a complete organism
Relationship Type: N - Non-molecular target assigned
Confidence: Target assigned is non-molecular

Data Source: SureChEMBL Patent Bioactivity Data
PubChem Standard ValueStandard TypeStandard RelationStandard ValueStandard UnitsActivity CommentData Validity Comment
EC50Not Determined
EC50Not Determined
2200EC50=2200000nMOutside typical range
50000EC50=50000000nMOutside typical range
700EC50=700000nMOutside typical range
EC50Not Determined
EC50Not Determined
1400EC50=1400000nMOutside typical range
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:N/A
External ID: SPEC167MG
Protocol: Tox21 Assay Protocol Summary:

5 uL of culture medium (DMEM containing 10% FBS) per well was dispensed into black wall/clear bottom 1536-well plates using a Multidrop Combi Dispenser (ThermoFisher Scientific, Waltham, MA). After 23 nL compound or DMSO vehicle was transferred into assay plate by a pintool work station (Kalypsys, San Diego, CA), fluorescence intensities in the assay plates were measured by an Envision (PerkinElmer, Shelton, CT) plate reader using three labels for measuring blue, green and red fluorescence at excitations 460, 535 and 590nm respectively.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent activators are ranked higher than compounds that showed apparent inhibition.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0005530000 uM-Replicate_1Activity at 0.00276 uM-Replicate_1Activity at 0.00765 uM-Replicate_1Activity at 0.012 uM-Replicate_1Activity at 0.024 uM-Replicate_1Activity at 0.034 uM-Replicate_1Activity at 0.074 uM-Replicate_1Activity at 0.148 uM-Replicate_1Activity at 0.199 uM-Replicate_1Activity at 0.370 uM-Replicate_1Activity at 0.743 uM-Replicate_1Activity at 1.207 uM-Replicate_1Activity at 1.859 uM-Replicate_1Activity at 3.722 uM-Replicate_1Activity at 9.170 uM-Replicate_1Activity at 13.42 uM-Replicate_1Activity at 18.62 uM-Replicate_1Activity at 45.97 uM-Replicate_1Activity at 91.34 uM-Replicate_1Activity at 95.67 uM-Replicate_1Activity at 202.9 uM-Replicate_1Activity at 354.0 uM-Replicate_1Activity at 920.3 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2Fit_InfiniteActivity-Replicate_2Fit_ZeroActivity-Replicate_2Fit_CurveClass-Replicate_2
Inactive040.10310.1406-0.03150.12620.060.1031QC'd by "NCI"0
Inactive040.02-0.0462-0.0096-0.0036-0.06880.02QC'd by "NCI"0
Inactive040.0352-0.02430.01330.08820.02270.0352QC'd by "NCI"0
Inactive04-0.0032-0.14120.03560.0067-0.0827-0.0032QC'd by "SigmaAldrich"0
Inactive04-0.0421-6.0E-4-0.01160.00418.0E-4-0.0421QC'd by "NCI"0
Inactive04-0.08870.05490.011900.0103-0.0887QC'd by "NCI"0
Inactive040.05490.14040.09660.0264-0.00150.0549QC'd by "NCI"0
Inactive04-0.0674-0.0024-0.1251-0.0771-0.0044-0.0674QC'd by "NCI"0
Inactive040.07660.11210.11820.1033-0.02320.0766QC'd by "NCI"0
Inactive040.02350.0289-0.01920.0237-0.01010.0235QC'd by "Labotest"0
Inactive04-1.0E-40.04880.0010.01740.0628-1.0E-4QC'd by "NCI"0
Inactive04-0.00820.10220.09650.07640.0317-0.0082QC'd by "NCI"0
Inactive040.04070.1229-0.00830.10480.07010.0407QC'd by "NCI"0
Inactive04-0.0682-0.10260.0427-0.0797-0.01-0.0682QC'd by "NCI"0
Inactive04-0.01790.0067-0.06430.0889-0.0161-0.0179QC'd by "NCI"0
Inactive04-0.0027-0.0933-0.0538-0.0212-0.0192-0.0027QC'd by "NCI"0
Inactive04-0.0156-0.0199-0.013-0.0358-0.0233-0.0156QC'd by "NCI"0
Inactive040.03220.01980.0576-0.00580.03020.0322QC'd by "Chembridge"0
Inactive040.10750.08580.07490.0633-0.01660.1075QC'd by "NCI"0
Inactive04-0.186-0.0569-0.018-0.0052-0.0633-0.186QC'd by "NCI"0
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:N/A
External ID: SPEC167MR
Protocol: Tox21 Assay Protocol Summary:

5 uL of culture medium (DMEM containing 10% FBS) per well was dispensed into black wall/clear bottom 1536-well plates using a Multidrop Combi Dispenser (ThermoFisher Scientific, Waltham, MA). After 23 nL compound or DMSO vehicle was transferred into assay plate by a pintool work station (Kalypsys, San Diego, CA), fluorescence intensities in the assay plates were measured by an Envision (PerkinElmer, Shelton, CT) plate reader using three labels for measuring blue, green and red fluorescence at excitations 460, 535 and 590nm respectively.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent activators are ranked higher than compounds that showed apparent inhibition.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0005530000 uM-Replicate_1Activity at 0.00276 uM-Replicate_1Activity at 0.00765 uM-Replicate_1Activity at 0.012 uM-Replicate_1Activity at 0.024 uM-Replicate_1Activity at 0.034 uM-Replicate_1Activity at 0.074 uM-Replicate_1Activity at 0.148 uM-Replicate_1Activity at 0.199 uM-Replicate_1Activity at 0.370 uM-Replicate_1Activity at 0.743 uM-Replicate_1Activity at 1.207 uM-Replicate_1Activity at 1.859 uM-Replicate_1Activity at 3.722 uM-Replicate_1Activity at 9.170 uM-Replicate_1Activity at 13.42 uM-Replicate_1Activity at 18.62 uM-Replicate_1Activity at 45.97 uM-Replicate_1Activity at 91.34 uM-Replicate_1Activity at 95.67 uM-Replicate_1Activity at 202.9 uM-Replicate_1Activity at 354.0 uM-Replicate_1Activity at 920.3 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2Fit_InfiniteActivity-Replicate_2Fit_ZeroActivity-Replicate_2Fit_CurveClass-Replicate_2
Inactive040.06820.17150.15520.2805-0.08310.0682QC'd by "APAC"0
Inactive040.0073-0.03930.005-0.09740.03070.0073QC'd by "APAC"0
Inactive04-0.4123-0.248-0.1541-0.1037-0.0973-0.4123QC'd by "APAC"0
Inactive040.19330.41050.28830.44640.38910.1933QC'd by "APAC"0
Inactive040.44160.65360.7260.63220.73960.4416QC'd by "APAC"0
Inactive040.2127-0.00470.08240.2587-0.01090.2127QC'd by "APAC"0
Inactive040.13480.40170.15030.02750.21030.1348QC'd by "APAC"0
Inactive040.16380.07840.19640.35280.10370.1638QC'd by "APAC"0
Inactive04-0.0775-0.1328-0.144-0.2205-0.105-0.0775QC'd by "APAC"0
Inactive040.12810.06390.0321-0.01010.04060.1281QC'd by "APAC"0
Inactive04-0.4235-0.3306-0.3534-0.2876-0.4525-0.4235QC'd by "APAC"0
Inactive040.1880.24950.21320.11330.30530.188QC'd by "APAC"0
Inactive040.26490.13370.33710.1823-0.01240.2649QC'd by "APAC"0
Inactive040.14720.44310.35470.41120.45620.1472QC'd by "APAC"0
Inactive040.18370.1140.0230.16450.38450.1837QC'd by "APAC"0
Inactive04-0.5082-0.4883-0.5711-0.5038-0.4992-0.5082QC'd by "APAC"0
Inactive04-0.2494-0.1585-0.0187-0.265-0.2494-0.2494QC'd by "APAC"0
Inactive04-0.489-0.6545-0.2063-0.2875-0.5573-0.489QC'd by "APAC"0
Inactive04-0.1512-0.1725-0.2697-0.1595-0.2932-0.1512QC'd by "APAC"0
Inactive040.1730.29550.30070.26150.34070.173QC'd by "APAC"0
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: epac1-activator-v
Protocol: Briefly, three uL of reagents (100 nM EPAC1, 250 nM RAP1B-BODIPY-GDP, 50 uM GDP) were dispensed into a 1536-well Greiner black solid-bottom medium binding assay plate. Controls and test compounds (23 nL) were transferred to the plate via a Kalypsys pin tool equipped with a 1536-pin array. The plates were centrifuged at 1,000 rpm for 15 seconds followed by 5 minute incubation at room temperature. The assay plates were read at 5 minute intervals for 30 minutes in the ViewLux plate reader using 480nm excitation and 540nm emission filters. The results were normalized to the agonist positive control of 6.5 mM cAMP.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent activators are ranked higher than compounds that showed apparent inhibition.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = 1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == 1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == 2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == 1.2 || ratio.curve_class == 2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds also have PUBCHEM_ACTIVITY_SCORE between 1 and 39.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.00123 uMActivity at 0.00610 uMActivity at 0.00630 uMActivity at 0.013 uMActivity at 0.025 uMActivity at 0.042 uMActivity at 0.068 uMActivity at 0.120 uMActivity at 0.202 uMActivity at 0.314 uMActivity at 0.611 uMActivity at 1.089 uMActivity at 1.568 uMActivity at 3.058 uMActivity at 5.503 uMActivity at 7.834 uMActivity at 15.29 uMActivity at 27.41 uMActivity at 39.61 uMActivity at 75.76 uMActivity at 149.6 uMActivity at 201.4 uMActivity at 319.7 uMActivity at 605.8 uMActivity at 817.0 uMCompound QC
Activator112.20182659.1944100Partial curve; high efficacy-3.954.50450.99882689.2430.04562.10 0 0 0 0 02175.7605-2.186418.44120.797383.3849426.79582175.7605QC'd by Microsource
Activator0.1778128.312895Complete curve; high efficacy-6.754.95490.9927134.48516.17231.10 0 0 0 0 114.5095.603324.7938142.7655131.831127.775314.509QC'd by SigmaAldrich
Activator0.4467126.107791Complete curve; high efficacy-6.351.86170.9998123.6363-2.47141.10 0 0 0 0 10.2688-2.58447.816180.257120.2764123.38950.2688QC'd by SigmaAldrich
Activator1.122117.125490Complete curve; high efficacy-5.952.24810.9788132.426515.30111.10 0 0 0 0143.318715.809439.5652122.9227119.7824143.3187QC'd by Tocris
Activator112.20181122.177671Partial curve; high efficacy-3.954.50450.99831140.568818.39122.10 0 0 0 0922.79033.23057.588941.6506204.8302922.7903QC'd by Timtec
Activator100709.567358Partial curve; high efficacy-43.990.9988700.7079-8.85942.10 0 0 0 0 0592.8155-15.9019-8.65324.5286-20.153176.4838592.8155QC'd by CarsonNewman-SPECS
Activator79.4328826.407657Partial curve; high efficacy-4.14.0950.9972826.76670.35912.10 0 0 0 0 0665.6736-2.5729-3.4508-16.761725.5851154.5978665.6736QC'd by Prestwick Chemical; Inc.
Activator100589.932555Partial curve; high efficacy-43.24750.984613.297923.36542.10 0 0 0 0 0498.6162-5.7471.05937.654362.5313194.9599498.6162QC'd by CarsonNewman-SPECS
Activator112.2018558.656655Partial curve; high efficacy-3.954.50450.9992557.2619-1.39472.10 0 0 0 0448.681-6.8565-3.87677.063281.1858448.681QC'd by Vitas
Activator100612.475355Partial curve; high efficacy-44.50450.9972611.2868-1.18852.10 0 0 0 0 0533.4091-10.048-5.6002-8.206821.4265142.7223533.4091QC'd by Pharmacopeia
Activator100511.551853Partial curve; high efficacy-44.44950.9965517.54675.9952.10 0 0 0 0 0453.9884-10.486710.44483.974421.1983121.4017453.9884QC'd by CarsonNewman-SPECS
Activator112.2018440.198152Partial curve; high efficacy-3.954.0950.9989439.2753-0.92282.10 0 0 0 0348.6312-5.1918-3.30186.970574.6909348.6312QC'd by Sequoia
Activator100497.63552Partial curve; high efficacy-43.67720.9977486.8252-10.80982.10 0 0 0 0 0401.671-14.9427-21.3461-13.18642.6858130.5049401.671QC'd by Pharmacopeia
Activator100438.508551Partial curve; high efficacy-44.95490.9987437.7956-0.71282.10 0 0 0 0 0392.29-7.25310.2913-4.1769.366693.145392.29QC'd by Pharmacopeia
Activator56.2341819.971850Partial curve; high efficacy-4.253.24750.9993802.9227-17.0492.10 0 0 0 0787.1792-7.4836-10.9833-14.2075580.1833787.1792QC'd by NCI
Activator112.2018363.64150Partial curve; high efficacy-3.954.95490.9972355.9752-7.66582.10 0 0 0 0 0293.7089-16.73630.4741-6.1211-4.368934.2599293.7089QC'd by Pharmacopeia
Activator112.2018363.029750Partial curve; high efficacy-3.954.50450.9992370.42997.40022.10 0 0 0 0 0299.70063.69434.700413.02825.857563.7543299.7006QC'd by Pharmacopeia
Activator100295.813448Partial curve; high efficacy-43.62720.9992302.03896.22552.10 0 0 0 0 0251.69912.67988.48118.67789.650486.3825251.6991QC'd by CarsonNewman-SPECS
Activator100233.346946Partial curve; high efficacy-44.50450.9961221.7227-11.62422.10 0 0 0 0 0192.4676-6.6471-16.5394-18.4762-5.603142.3638192.4676QC'd by CarsonNewman-SPECS
Activator112.2018234.606146Partial curve; high efficacy-3.954.95490.984235.23560.62952.10 0 0 0 0 0197.01480.9163-4.51361.948217.44218.7867197.0148QC'd by Pharmacopeia
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:N/A
External ID: SPEC167CG
Protocol: Tox21 Assay Protocol Summary:

2,000 HEK293 cells in 5 uL of culture medium containing 10% dialyzed FBS per well were dispensed into black wall/clear bottom 1536-well plates using a Multidrop Combi Dispenser (Thermo Scientific). The assay plates were incubated for 4-5 hr at 37C to allow cell attachment to the well bottom, followed by the transfer of 23 nL compound or DMSO vehicle by a pintool work station (Kalypsys, San Diego, CA). After the assay plates were incubated overnight at 37C and 5% CO2, fluorescence intensities in the assay plates were measured by an Envision (PerkinElmer, Shelton, CT) plate reader using three labels for measuring blue, green and red fluorescence at excitations 460, 535 and 590nm respectively.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent activators are ranked higher than compounds that showed apparent inhibition.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0005530000 uM-Replicate_1Activity at 0.00276 uM-Replicate_1Activity at 0.00765 uM-Replicate_1Activity at 0.012 uM-Replicate_1Activity at 0.024 uM-Replicate_1Activity at 0.034 uM-Replicate_1Activity at 0.074 uM-Replicate_1Activity at 0.148 uM-Replicate_1Activity at 0.199 uM-Replicate_1Activity at 0.370 uM-Replicate_1Activity at 0.743 uM-Replicate_1Activity at 1.207 uM-Replicate_1Activity at 1.859 uM-Replicate_1Activity at 3.722 uM-Replicate_1Activity at 9.170 uM-Replicate_1Activity at 13.42 uM-Replicate_1Activity at 18.62 uM-Replicate_1Activity at 45.97 uM-Replicate_1Activity at 91.34 uM-Replicate_1Activity at 95.67 uM-Replicate_1Activity at 202.9 uM-Replicate_1Activity at 354.0 uM-Replicate_1Activity at 920.3 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2Fit_InfiniteActivity-Replicate_2Fit_ZeroActivity-Replicate_2Fit_CurveClass-Replicate_2
Inactive04-0.0303-0.04260.0285-0.09190.0085-0.0303QC'd by "NCI"0
Inactive040.0853-0.06580.02019.0E-40.06280.0853QC'd by "NCI"0
Inactive040.16730.04180.01560.0204-0.00980.1673QC'd by "NCI"0
Inactive04-0.1980.02190.0160.02350.0689-0.198QC'd by "SigmaAldrich"0
Inactive040.0038-0.0014-0.00825.0E-4-0.1170.0038QC'd by "NCI"0
Inactive040.0026-0.0041-0.01760.0697-0.01480.0026QC'd by "NCI"0
Inactive040.1333-0.0845-0.0206-0.01310.12030.1333QC'd by "NCI"0
Inactive040.03690.00440.0618-0.01070.01570.0369QC'd by "NCI"0
Inactive04-0.02150.02550.01530.1030.0492-0.0215QC'd by "NCI"0
Inactive04-0.00280.08780.0034-0.01623.0E-4-0.0028QC'd by "Labotest"0
Inactive040.02210.0083-0.0285-0.04060.10790.0221QC'd by "NCI"0
Inactive040.02430.10020.08470.0514-0.00220.0243QC'd by "NCI"0
Inactive040.00680.024-0.00130.0328-0.11050.0068QC'd by "NCI"0
Inactive040.03090.0251-0.2255-0.1044-0.07930.0309QC'd by "NCI"0
Inactive04-0.0428-0.0779-0.07410.0110.0229-0.0428QC'd by "NCI"0
Inactive040.07660.0357-0.02130.0861-0.01260.0766QC'd by "NCI"0
Inactive04-0.0349-0.0548-0.0746-0.0452-0.1742-0.0349QC'd by "NCI"0
Inactive040.15650.01040.0178-0.0320.02410.1565QC'd by "Chembridge"0
Inactive04-0.05070.0691-0.01840.01950.0897-0.0507QC'd by "NCI"0
Inactive04-0.0232-0.1816-0.1161-0.2126-0.2187-0.0232QC'd by "NCI"0
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: epac1-inhibitor-v
Protocol: Briefly, three uL of reagents (100 nM EPAC1, 250 nM RAP1B-BODIPY-GDP, 50 uM GDP) were dispensed into a 1536-well Greiner black solid-bottom medium binding assay plate. Controls and test compounds (23 nL) were transferred to the plate via a Kalypsys pin tool equipped with a 1536-pin array. The plates were centrifuged at 1,000 rpm for 15 seconds followed by 5 minute incubation at room temperature. The assay plates were read at 5 minute intervals for 30 minutes in the ViewLux plate reader using 480nm excitation and 540nm emission filters. The results were normalized to the agonist positive control ATA and DMSO.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.00123 uMActivity at 0.00610 uMActivity at 0.00630 uMActivity at 0.013 uMActivity at 0.025 uMActivity at 0.042 uMActivity at 0.068 uMActivity at 0.120 uMActivity at 0.202 uMActivity at 0.314 uMActivity at 0.611 uMActivity at 1.089 uMActivity at 1.568 uMActivity at 3.058 uMActivity at 5.503 uMActivity at 7.834 uMActivity at 15.29 uMActivity at 27.41 uMActivity at 39.61 uMActivity at 75.76 uMActivity at 149.6 uMActivity at 201.4 uMActivity at 319.7 uMActivity at 605.8 uMActivity at 817.0 uMCompound QC
Inactive04.95490.78241.505912.540 0 0 0 0 02.50148.657916.73337.679-0.41183.23982.5014QC'd by Pharmacopeia
Inactive04.95490.5059222.540 0 0 0 0 06.253623.167131.574120.397112.323123.69316.2536QC'd by Pharmacopeia
Inactive03.06540.487561440 0 0 0 0 07.117813.853713.063510.239619.91049.84967.1178QC'd by Pharmacopeia
Inactive04.95490.8513-6.122214.540 0 0 0 0 0-2.601918.618115.697111.958910.649712.3116-2.6019QC'd by Pharmacopeia
Inactive04.95490.4441-8.935340 0 0 0 0 04.128-6.61282.85915.135-4.2457-1.68664.128QC'd by Pharmacopeia
Inactive00.90.60781.5740 0 0 0 0 03.28024.93557.52122.24671.45360.76263.2802QC'd by Pharmacopeia
Inactive0415.807823.846715.21025.400717.117711.703815.8078QC'd by Pharmacopeia
Inactive04-4.32494.35640.9262-8.26096.61363.2318-4.3249QC'd by Pharmacopeia
Inactive04.95490.3866.51640 0 0 0 0 118.561314.469622.616710.242516.25858.074118.5613QC'd by Pharmacopeia
Inactive04.95490.793515-5.385140 0 0 0 0 016.1015-1.154320.964112.456114.239511.422716.1015QC'd by Pharmacopeia
Inactive04.50450.947310.52240 0 0 0 0 08.684621.396522.306312.781710.406512.7248.6846QC'd by Pharmacopeia
Inactive00.90.72282.68042640 0 0 0 0 0-2.766319.58196.42455.7298.03594.8741-2.7663QC'd by Pharmacopeia
Inactive04.44950.86116.58.540 0 0 0 0 19.3158.510610.85386.227115.368416.53989.315QC'd by Pharmacopeia
Inactive04.95490.574110.50.708340 0 0 0 0 012.21914.1249-2.326514.46343.839910.786612.2191QC'd by Pharmacopeia
Inactive049.708413.42218.37480.333810.101818.04579.7084QC'd by Pharmacopeia
Inactive04.95490.4502-7.41418.540 0 0 0 0 0-4.51189.055914.9898-2.014610.28748.4395-4.5118QC'd by Pharmacopeia
Inactive04.95490.6758280.244340 0 0 0 0 023.04957.0826-6.46314.13492.386-6.030223.0495QC'd by Pharmacopeia
Inactive04.44950.7608-2.59256.540 0 0 0 0 18.96953.44595.67689.8855-0.0456-2.16048.9695QC'd by Pharmacopeia
Inactive02.63840.66513.52040 0 0 0 0 013.574216.035922.509821.272319.386214.340813.5742QC'd by Pharmacopeia
Inactive04-3.2632-16.2622-13.7616-11.6684-9.5243-17.6211-3.2632QC'd by Prestwick Chemical; Inc.
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:N/A
External ID: SPEC167MB
Protocol: Tox21 Assay Protocol Summary:

5 uL of culture medium (DMEM containing 10% FBS) per well was dispensed into black wall/clear bottom 1536-well plates using a Multidrop Combi Dispenser (ThermoFisher Scientific, Waltham, MA). After 23 nL compound or DMSO vehicle was transferred into assay plate by a pintool work station (Kalypsys, San Diego, CA), fluorescence intensities in the assay plates were measured by an Envision (PerkinElmer, Shelton, CT) plate reader using three labels for measuring blue, green and red fluorescence at excitations 460, 535 and 590nm respectively.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent activators are ranked higher than compounds that showed apparent inhibition.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0005530000 uM-Replicate_1Activity at 0.00276 uM-Replicate_1Activity at 0.00765 uM-Replicate_1Activity at 0.012 uM-Replicate_1Activity at 0.024 uM-Replicate_1Activity at 0.034 uM-Replicate_1Activity at 0.074 uM-Replicate_1Activity at 0.148 uM-Replicate_1Activity at 0.199 uM-Replicate_1Activity at 0.370 uM-Replicate_1Activity at 0.743 uM-Replicate_1Activity at 1.207 uM-Replicate_1Activity at 1.859 uM-Replicate_1Activity at 3.722 uM-Replicate_1Activity at 9.170 uM-Replicate_1Activity at 13.42 uM-Replicate_1Activity at 18.62 uM-Replicate_1Activity at 45.97 uM-Replicate_1Activity at 91.34 uM-Replicate_1Activity at 95.67 uM-Replicate_1Activity at 202.9 uM-Replicate_1Activity at 354.0 uM-Replicate_1Activity at 920.3 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2Fit_InfiniteActivity-Replicate_2Fit_ZeroActivity-Replicate_2Fit_CurveClass-Replicate_2
Inactive04-0.060.0769-0.0561-0.05340.0765-0.06QC'd by "NCI"0
Inactive04-0.02860.01850.15430.03970.0134-0.0286QC'd by "NCI"0
Inactive041.25510.11730.01450.07070.51551.2551QC'd by "NCI"0
Inactive040.0380.0229-0.1395-0.01880.42040.038QC'd by "SigmaAldrich"0
Inactive041.3250.07660.1836-0.10240.07711.325QC'd by "NCI"0
Inactive040.1088-0.12430.0941-0.0246-0.04550.1088QC'd by "NCI"0
Inactive040.00260.0529-0.1116-0.1678-0.11720.0026QC'd by "NCI"0
Inactive040.17340.0511-0.06420.11-0.13760.1734QC'd by "NCI"0
Inactive040.0031-0.0257-0.0731-0.021-0.01490.0031QC'd by "NCI"0
Inactive04.0950.98722.5040 0 0 0 02.51080.00570.26280.01340.77542.5108QC'd by "Labotest"0
Inactive04-0.05950.0115-0.03130.04540.0652-0.0595QC'd by "NCI"0
Inactive040.7551-0.0030.0690.14220.06940.7551QC'd by "NCI"0
Inactive04-0.0762-0.099-0.14750.0756-0.1338-0.0762QC'd by "NCI"0
Inactive040.0533-0.1182-0.00850.0808-0.08810.0533QC'd by "NCI"0
Inactive041.4117-0.0519-0.0295-0.05670.23241.4117QC'd by "NCI"0
Inactive040.15250.02280.10290.03280.11910.1525QC'd by "NCI"0
Inactive040.97520.1286-0.0289-0.0041-0.01590.9752QC'd by "NCI"0
Inactive040.090.11160.0522-0.0224-0.17680.09QC'd by "Chembridge"0
Inactive040.12760.09120.04220.0790.08710.1276QC'd by "NCI"0
Inactive04-0.05040.00170.0374-0.2014-0.0226-0.0504QC'd by "NCI"0
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:N/A
External ID: SPEC478MG
Protocol: Tox21 Assay Protocol Summary:

5 uL of culture medium (MEM containing 10% FBS) per well was dispensed into black wall/clear bottom 1536-well plates using a Multidrop Combi Dispenser (ThermoFisher Scientific, Waltham, MA). After 23 nL compound or DMSO vehicle was transferred into assay plate by a pintool work station (Kalypsys, San Diego, CA), fluorescence intensities in the assay plates were measured by an Envision (PerkinElmer, Shelton, CT) plate reader using three labels for measuring blue, green and red fluorescence at excitations 460, 535 and 590nm respectively.
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent activators are ranked higher than compounds that showed apparent inhibition.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.

Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0005530000 uM-Replicate_1Activity at 0.00276 uM-Replicate_1Activity at 0.00765 uM-Replicate_1Activity at 0.012 uM-Replicate_1Activity at 0.024 uM-Replicate_1Activity at 0.034 uM-Replicate_1Activity at 0.074 uM-Replicate_1Activity at 0.148 uM-Replicate_1Activity at 0.199 uM-Replicate_1Activity at 0.370 uM-Replicate_1Activity at 0.743 uM-Replicate_1Activity at 1.207 uM-Replicate_1Activity at 1.859 uM-Replicate_1Activity at 3.722 uM-Replicate_1Activity at 9.170 uM-Replicate_1Activity at 13.42 uM-Replicate_1Activity at 18.62 uM-Replicate_1Activity at 45.97 uM-Replicate_1Activity at 91.34 uM-Replicate_1Activity at 95.67 uM-Replicate_1Activity at 202.9 uM-Replicate_1Activity at 354.0 uM-Replicate_1Activity at 920.3 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2Fit_InfiniteActivity-Replicate_2Fit_ZeroActivity-Replicate_2Fit_CurveClass-Replicate_2
Inactive04-0.0468-1.0E-4-0.0634-0.0128-0.1309-0.0468QC'd by "NCI"0
Inactive04-0.02170.0466-0.04120.00330.0551-0.0217QC'd by "NCI"0
Inactive04-0.0248-0.00450.0622-0.03730.0284-0.0248QC'd by "NCI"0
Inactive040.01860.0540.055-7.0E-40.08120.0186QC'd by "SigmaAldrich"0
Inactive040.02420.07270.1578-0.01480.02860.0242QC'd by "NCI"0
Inactive040.08870.03620.13790.04160.03120.0887QC'd by "NCI"0
Inactive040.10310.0424-0.0028-0.06470.0120.1031QC'd by "NCI"0
Inactive040.022-0.01990.0104-0.01420.03070.022QC'd by "NCI"0
Inactive040.58190.1190.05910.03290.05860.5819QC'd by "NCI"0
Inactive04-0.01230.04580.0457-0.03880.0399-0.0123QC'd by "Labotest"0
Inactive04-0.0094-0.02560.0289-0.00760-0.0094QC'd by "NCI"0
Inactive040.11950.07450.00670.004-0.05970.1195QC'd by "NCI"0
Inactive04-0.0059-0.05640.01470.0049-0.0156-0.0059QC'd by "NCI"0
Inactive04-0.05470.0295-0.0247-0.0665-0.0356-0.0547QC'd by "NCI"0
Inactive04-0.0413-0.0059-0.1195-0.0027-0.0175-0.0413QC'd by "NCI"0
Inactive040.175-0.00450.11290.06590.06270.175QC'd by "NCI"0
Inactive04-0.0317-0.0316-0.01050.0141-0.0074-0.0317QC'd by "NCI"0
Inactive040.06210.0243-0.0520.16910.01120.0621QC'd by "Chembridge"0
Inactive040.0158-0.02480.0493-0.0242-0.02880.0158QC'd by "NCI"0
Inactive04-0.0654-0.1331-0.0734-0.03930.0109-0.0654QC'd by "NCI"0
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:N/A
External ID: SPEC478CB
Protocol: Tox21 Assay Protocol Summary:

2,000 HepG2 cells in 5 uL of culture medium (MEM containing 10% FBS) per well were dispensed into black wall/clear bottom 1536-well plates using a Multidrop Combi Dispenser (ThermoFisher Scientific, Waltham, MA). The assay plates were incubated overnight at 37 C to allow cell attachment to the well bottom, followed by the transfer of 23 nL compound or DMSO vehicle by a pintool work station (Kalypsys , San Diego, CA). After the assay plates were incubated for 1 hr at 37 C and 5% CO2, fluorescence intensities in the assay plates were measured by an Envision (PerkinElmer, Shelton, CT) plate reader using three labels for measuring blue, green and red fluorescence at excitations 460, 535 and 590 nm respectively.
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent activators are ranked higher than compounds that showed apparent inhibition.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.

Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0005530000 uM-Replicate_1Activity at 0.00276 uM-Replicate_1Activity at 0.00765 uM-Replicate_1Activity at 0.012 uM-Replicate_1Activity at 0.024 uM-Replicate_1Activity at 0.034 uM-Replicate_1Activity at 0.074 uM-Replicate_1Activity at 0.148 uM-Replicate_1Activity at 0.199 uM-Replicate_1Activity at 0.370 uM-Replicate_1Activity at 0.743 uM-Replicate_1Activity at 1.207 uM-Replicate_1Activity at 1.859 uM-Replicate_1Activity at 3.722 uM-Replicate_1Activity at 9.170 uM-Replicate_1Activity at 13.42 uM-Replicate_1Activity at 18.62 uM-Replicate_1Activity at 45.97 uM-Replicate_1Activity at 91.34 uM-Replicate_1Activity at 95.67 uM-Replicate_1Activity at 202.9 uM-Replicate_1Activity at 354.0 uM-Replicate_1Activity at 920.3 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2Fit_InfiniteActivity-Replicate_2Fit_ZeroActivity-Replicate_2Fit_CurveClass-Replicate_2
Inactive040.2003-0.01150.00710.23730.09540.2003QC'd by "NCI"0
Inactive040.1113-0.03910.08984.0E-4-0.03890.1113QC'd by "NCI"0
Inactive04-0.09730.0277-0.0084-0.00980.0055-0.0973QC'd by "NCI"0
Inactive04-0.1827-0.0289-0.0224-0.1537-0.0181-0.1827QC'd by "SigmaAldrich"0
Inactive040.5452-0.03350.0032-0.01370.01630.5452QC'd by "NCI"0
Inactive04-0.05130.011-0.0106-0.0503-0.0065-0.0513QC'd by "NCI"0
Inactive04-0.0252-0.1196-0.0502-0.05650.0376-0.0252QC'd by "NCI"0
Inactive040.10450.0373-0.01590.03940.00210.1045QC'd by "NCI"0
Inactive04-0.24220.0063-0.0071-0.0119-0.0133-0.2422QC'd by "NCI"0
Inactive04.50450.98673040 0 0 0 03.1340.15520.13580.19860.6053.134QC'd by "Labotest"0
Inactive04-0.0090.01850.03930.2310.0436-0.009QC'd by "NCI"0
Inactive040.07510.02710.22620.17550.01740.0751QC'd by "NCI"0
Inactive040.0132-0.0598-0.0350.09430.07230.0132QC'd by "NCI"0
Inactive049.0E-4-0.0911-0.05740.15930.17099.0E-4QC'd by "NCI"0
Inactive040.6834-0.1194-0.00280.3720.19860.6834QC'd by "NCI"0
Inactive040.1104-0.08290.06180.16230.0230.1104QC'd by "NCI"0
Inactive040.5456-0.0786-0.0186-0.0058-0.00230.5456QC'd by "NCI"0
Inactive04-0.1424-0.0976-0.10020.027-0.1146-0.1424QC'd by "Chembridge"0
Inactive040.0252-0.0593-0.08240.12910.04990.0252QC'd by "NCI"0
Inactive040.0384-0.2038-0.1551-0.007-0.01920.0384QC'd by "NCI"0
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: epac2-activator-v2
Protocol: Briefly, three uL of reagents (100 nM EPAC2, 250 nM RAP1B-BODIPY-GDP, 50 uM GDP) were dispensed into a 1536-well Greiner black solid-bottom medium binding assay plate. Controls and test compounds (23 nL) were transferred to the plate via a Kalypsys pin tool equipped with a 1536-pin array. The plates were centrifuged at 1,000 rpm for 15 seconds followed by 5 minute incubation at room temperature. The assay plates were read at 5 minute intervals for 30 minutes in the ViewLux plate reader using 480nm excitation and 540nm emission filters. The results were normalized to the agonist positive control of 6.5 mM cAMP.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent activators are ranked higher than compounds that showed apparent inhibition.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = 1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == 1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == 2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == 1.2 || ratio.curve_class == 2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds also have PUBCHEM_ACTIVITY_SCORE between 1 and 39.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.00123 uMActivity at 0.00246 uMActivity at 0.00610 uMActivity at 0.00630 uMActivity at 0.011 uMActivity at 0.025 uMActivity at 0.045 uMActivity at 0.067 uMActivity at 0.120 uMActivity at 0.202 uMActivity at 0.314 uMActivity at 0.611 uMActivity at 1.089 uMActivity at 1.568 uMActivity at 3.058 uMActivity at 5.503 uMActivity at 7.834 uMActivity at 15.29 uMActivity at 27.41 uMActivity at 39.61 uMActivity at 75.76 uMActivity at 149.6 uMActivity at 201.4 uMActivity at 319.7 uMActivity at 605.8 uMActivity at 817.0 uMCompound QC
Inactive04.95490.8563-9.9979-3.18240 0 0 0 0 0-8.823-2.9167-5.5515-1.8183-11.2482-10.2408-8.823QC'd by Microsource
Inactive01.53860.5644-4.854640 0 0 0 0 1-7.5471-0.6835-9.0455-3.7039-1.19033.153-7.5471QC'd by Microsource
Inactive04.95490.431-21.09492.199340 0 0 0 0 0-29.6624-1.0839-27.7771-29.2982-9.5254-9.846-29.6624QC'd by Microsource
Inactive04.95490.3341-1.3603-6.912440 0 0 0 0 1-15.5699-9.927-2.5767-5.8552-8.5221-2.3836-15.5699QC'd by Microsource
Inhibitor0.891314.13510Complete curve; partial efficacy; poor fit-6.052.12110.6534-22.6728-8.5377-1.40 0 0 0 0 0-21.1521-8.7814-12.9514-21.2535-30.9774-17.0722-21.1521QC'd by Microsource
Inactive03.1320.47250.5-4.228440 0 0 0 0 0-0.2612-1.9763-2.0592-8.107-2.12880.8201-0.2612QC'd by Microsource
Inactive04.95490.4917-10.967-2.314940 0 0 0 0 0-10.1405-1.5124-2.5506-5.4129-17.8892-4.0897-10.1405QC'd by Microsource
Inactive03.990.5924-19.9348040 0 0 0 0 0-28.6957-6.23025.7918-15.0449-23.6413-7.309-28.6957QC'd by Microsource
Inactive04.95490.4102-6.1308540 0 0 0 0 0-4.3550.82898.6021-2.8349-16.3592.161-4.355QC'd by Microsource
Inactive04.95490.369-1.5-14.336940 0 0 0 0 1-9.3021-12.78082.0015-0.2528-12.58754.4401-9.3021QC'd by Microsource
Inhibitor0.707923.62210Complete curve; partial efficacy; poor fit-6.153.06540.6513-24.5288-0.9067-1.40 0 0 0 0 1-13.9864-1.5889-9.6741-27.4469-33.3677-12.1786-13.9864QC'd by Microsource
Inactive04-22.4775-11.6889-11.6628-13.5576-20.9035-8.6191-22.4775QC'd by Microsource
Inactive00.80.7088-25.4933-11.691840 0 0 0 0 0-24.5778-16.5266-8.0765-17.2318-20.0221-22.1348-24.5778QC'd by Microsource
Inhibitor0.177819.99850Complete curve; partial efficacy; poor fit-6.754.95490.6578-21.9347-1.9361-1.40 0 0 0 0 0-23.6561-4.5301-30.7789-20.7284-19.2667-15.4849-23.6561QC'd by Microsource
Inactive010.9184-24.9585-2.733140 0 0 0 0 1-15.8401-9.7776-20.4013-20.4952-26.2154-25.1202-15.8401QC'd by Microsource
Inactive04-16.8662-15.0798-16.9114-17.163-13.1564-16.5558-16.8662QC'd by Microsource
Inactive047.75753.31266.13836.2047-2.02096.22127.7575QC'd by Microsource
Inactive043.75979.79097.02243.0975-6.896512.31463.7597QC'd by Microsource
Inactive04.95490.6335-4.9129640 0 0 0 0 0-8.84676.11915.34965.0731-9.09412.984-8.8467QC'd by Microsource
Inactive04.95490.7097-7.2734040 0 0 0 0 0-5.9151.1538-1.05870.2688-11.4778-4.1213-5.915QC'd by Microsource
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:N/A
External ID: SPEC478MR
Protocol: Tox21 Assay Protocol Summary:

5 uL of culture medium (MEM containing 10% FBS) per well was dispensed into black wall/clear bottom 1536-well plates using a Multidrop Combi Dispenser (ThermoFisher Scientific, Waltham, MA). After 23 nL compound or DMSO vehicle was transferred into assay plate by a pintool work station (Kalypsys, San Diego, CA), fluorescence intensities in the assay plates were measured by an Envision (PerkinElmer, Shelton, CT) plate reader using three labels for measuring blue, green and red fluorescence at excitations 460, 535 and 590nm respectively.
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent activators are ranked higher than compounds that showed apparent inhibition.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.

Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0005530000 uM-Replicate_1Activity at 0.00276 uM-Replicate_1Activity at 0.00765 uM-Replicate_1Activity at 0.012 uM-Replicate_1Activity at 0.024 uM-Replicate_1Activity at 0.034 uM-Replicate_1Activity at 0.074 uM-Replicate_1Activity at 0.148 uM-Replicate_1Activity at 0.199 uM-Replicate_1Activity at 0.370 uM-Replicate_1Activity at 0.743 uM-Replicate_1Activity at 1.207 uM-Replicate_1Activity at 1.859 uM-Replicate_1Activity at 3.722 uM-Replicate_1Activity at 9.170 uM-Replicate_1Activity at 13.42 uM-Replicate_1Activity at 18.62 uM-Replicate_1Activity at 45.97 uM-Replicate_1Activity at 91.34 uM-Replicate_1Activity at 95.67 uM-Replicate_1Activity at 202.9 uM-Replicate_1Activity at 354.0 uM-Replicate_1Activity at 920.3 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2Fit_InfiniteActivity-Replicate_2Fit_ZeroActivity-Replicate_2Fit_CurveClass-Replicate_2
Inactive04-0.12420.2628-0.1782-0.4447-0.2156-0.1242QC'd by "NCI"0
Inactive040.52820.2696-0.353-0.2319-0.17610.5282QC'd by "NCI"0
Inactive040.36990.109-0.00360.2172-0.0050.3699QC'd by "NCI"0
Inactive040.003-0.1398-0.2166-0.05930.03410.003QC'd by "SigmaAldrich"0
Inactive040.0037-0.18840.15210.18170.12320.0037QC'd by "NCI"0
Inactive040.42260.0606-0.0267-0.1598-0.03750.4226QC'd by "NCI"0
Inactive04-0.1083-0.0289-0.054-0.2945-0.072-0.1083QC'd by "NCI"0
Inactive04-0.0618-0.03660.04-0.2576-0.1156-0.0618QC'd by "NCI"0
Inactive040.0450.2884-0.027-0.166-0.30740.045QC'd by "NCI"0
Inactive04-0.2251-0.37-0.4364-0.0983-0.1209-0.2251QC'd by "Labotest"0
Inactive04-0.32420.23140.0134-0.2318-0.0596-0.3242QC'd by "NCI"0
Inactive04-0.01610.01530.03390.01490.0696-0.0161QC'd by "NCI"0
Inactive04-0.00830.0949-0.2516-0.1363-0.3201-0.0083QC'd by "NCI"0
Inactive040.1281-0.3790.11360.0866-0.02890.1281QC'd by "NCI"0
Inactive04-0.0989-0.0902-0.1041-0.2289-0.1987-0.0989QC'd by "NCI"0
Inactive040.0739-0.0110.01860.02430.02880.0739QC'd by "NCI"0
Inactive04-0.20280.08760.015-0.0122-0.012-0.2028QC'd by "NCI"0
Inactive04-0.152-0.0722-0.03940.08260.0334-0.152QC'd by "Chembridge"0
Inactive04-0.0720.1489-0.00810.015-0.0036-0.072QC'd by "NCI"0
Inactive04-0.1159-0.19220.11950.16620.2987-0.1159QC'd by "NCI"0
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: epac2-inhibitor-v2
Protocol: Briefly, three uL of reagents (100 nM EPAC2, 250 nM RAP1B-BODIPY-GDP, 50 uM GDP) were dispensed into a 1536-well Greiner black solid-bottom medium binding assay plate. Controls and test compounds (23 nL) were transferred to the plate via a Kalypsys pin tool equipped with a 1536-pin array. The plates were centrifuged at 1,000 rpm for 15 seconds followed by 5 minute incubation at room temperature. The assay plates were read at 5 minute intervals for 30 minutes in the ViewLux plate reader using 480nm excitation and 540nm emission filters. The results were normalized to the agonist positive control of 6.5 mM cAMP.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0009200000 uMActivity at 0.00184 uMActivity at 0.00456 uMActivity at 0.00471 uMActivity at 0.00850 uMActivity at 0.018 uMActivity at 0.034 uMActivity at 0.050 uMActivity at 0.090 uMActivity at 0.151 uMActivity at 0.235 uMActivity at 0.457 uMActivity at 0.814 uMActivity at 1.171 uMActivity at 2.284 uMActivity at 4.113 uMActivity at 5.853 uMActivity at 11.42 uMActivity at 20.49 uMActivity at 29.59 uMActivity at 56.64 uMActivity at 111.7 uMActivity at 150.6 uMActivity at 238.8 uMActivity at 452.6 uMActivity at 611.0 uMCompound QC
Inactive03.62720.8626-16.9749340 0 0 0 0 0-11.35224.4122-0.18693.8551-9.0486-22.4791-11.3522QC'd by SigmaAldrich
Inactive01.210.9115126.540 0 0 0 0 03.087922.522231.966122.849617.27176.55893.0879QC'd by NCI
Inactive00.30.7243-12.89953840 0 0 0 0 0-10.749628.516821.95465.20966.073811.3009-10.7496QC'd by Prestwick Chemical; Inc.
Inactive04.95490.8029-15.6993-1.540 0 0 0 0 0-11.416-1.5504-1.249-4.6581-0.42660.4639-11.416QC'd by BIOMOL
Inactive04.95490.6678-24.46023.435940 0 0 0 0 1-5.46512.8722.434-38.4104-25.2406-9.2436-5.4651QC'd by BIOMOL
Inactive02.40640.421511740 0 0 0 0 05.872919.320214.88288.633224.90711.29795.8729QC'd by BIOMOL
Inactive00.60.7078-8.313814.540 0 0 0 0 0-10.777711.81871.99321.9062-11.5115-0.0866-10.7777QC'd by BIOMOL
Inactive03.990.91612.52940 0 0 0 0 011.321625.351110.278212.692812.042515.059611.3216QC'd by BIOMOL
Inactive04.95490.7598-8.0307240 0 0 0 0 0-6.9632-1.91335.8317-9.609-8.7246-6.018-6.9632QC'd by SigmaAldrich
Inactive00.70.6402-18.8089-2.373540 0 0 0 0 0-14.8407-3.9662-6.7181-0.3112-9.968-9.2615-14.8407QC'd by Microsource
Inactive04.95490.9739-11.7501240 0 0 0 0 0-11.69293.0780.24372.2683-12.7084-10.568-11.6929QC'd by Microsource
Inactive00.50.7605-11.0605640 0 0 0 0 0-14.63373.6876-3.5123-6.8473-7.5675-5.2666-14.6337QC'd by BIOMOL
Inactive04-7.534.7778-6.7829-15.1322-23.6499.0847-7.53QC'd by Prestwick Chemical; Inc.
Inactive04.95490.6409-3.29491440 0 0 0 0 112.981817.6514.10220.62192.497-3.579112.9818QC'd by BIOMOL
Inactive01.82650.7407-32.7287-10.937340 0 0 0 0 0-28.3802-13.7631-19.1044-5.7811-12.8137-32.2739-28.3802QC'd by Tocris
Activator39.810746.5380Single point of activity-4.44.44950.745456.645810.107830 0 0 0 0 117.141513.503225.583214.4646.953849.110217.1415QC'd by SigmaAldrich
Inactive04.95490.5359-17.72063.540 0 0 0 0 0-16.8505-6.86613.1002-5.400912.3928-11.0619-16.8505QC'd by SigmaAldrich
Inactive04.95490.6571.108210.540 0 0 0 0 110.717211.35185.125315.2488-0.32652.247610.7172QC'd by Prestwick Chemical; Inc.
Inactive00.70.842-14.440710.540 0 0 0 0 0-8.700613.02386.27927.28923.56910.9878-8.7006QC'd by BIOMOL
Inactive01.010.87182.4065-26.947540 0 0 0 0 1-20.1909-25.9748-30.373-20.9376-21.2882-7.9946-20.1909QC'd by Prestwick Chemical; Inc.
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:N/A
External ID: SPEC478MB
Protocol: Tox21 Assay Protocol Summary:

5 uL of culture medium (MEM containing 10% FBS) per well was dispensed into black wall/clear bottom 1536-well plates using a Multidrop Combi Dispenser (ThermoFisher Scientific, Waltham, MA). After 23 nL compound or DMSO vehicle was transferred into assay plate by a pintool work station (Kalypsys, San Diego, CA), fluorescence intensities in the assay plates were measured by an Envision (PerkinElmer, Shelton, CT) plate reader using three labels for measuring blue, green and red fluorescence at excitations 460, 535 and 590nm respectively.
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent activators are ranked higher than compounds that showed apparent inhibition.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.

Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0005530000 uM-Replicate_1Activity at 0.00276 uM-Replicate_1Activity at 0.00765 uM-Replicate_1Activity at 0.012 uM-Replicate_1Activity at 0.024 uM-Replicate_1Activity at 0.034 uM-Replicate_1Activity at 0.074 uM-Replicate_1Activity at 0.148 uM-Replicate_1Activity at 0.199 uM-Replicate_1Activity at 0.370 uM-Replicate_1Activity at 0.743 uM-Replicate_1Activity at 1.207 uM-Replicate_1Activity at 1.859 uM-Replicate_1Activity at 3.722 uM-Replicate_1Activity at 9.170 uM-Replicate_1Activity at 13.42 uM-Replicate_1Activity at 18.62 uM-Replicate_1Activity at 45.97 uM-Replicate_1Activity at 91.34 uM-Replicate_1Activity at 95.67 uM-Replicate_1Activity at 202.9 uM-Replicate_1Activity at 354.0 uM-Replicate_1Activity at 920.3 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2Fit_InfiniteActivity-Replicate_2Fit_ZeroActivity-Replicate_2Fit_CurveClass-Replicate_2
Inactive04-0.1115-0.1251-0.0765-0.06640.0949-0.1115QC'd by "SIGMA"0
Inactive04-0.0069-0.10850.02610.0208-0.0462-0.0069QC'd by "SigmaAldrich"0
Inactive04-0.172-0.0309-0.0124-0.0718-0.0262-0.172QC'd by "SIGMA"0
Inactive040.0130.0073-0.01730.01340.00240.013QC'd by "SigmaAldrich"0
Inactive04-0.052-0.0612-0.0736-0.0496-0.0413-0.052QC'd by "SigmaAldrich"0
Inactive04-0.0569-0.01650.10050.1139-0.0959-0.0569QC'd by "SigmaAldrich"0
Inactive04-0.0353-0.0623-0.04670.00960.0134-0.0353QC'd by "SIGMA"0
Inactive040.22820.00980.01520.0163-0.02330.2282QC'd by "Alfa Aesar"0
Inactive04-0.1287-0.0353-0.0866-0.012-0.0014-0.1287QC'd by "SIGMA"0
Inactive04-0.0565-0.1141-0.0255-0.009-0.0415-0.0565QC'd by "SIGMA"Inactive04
Inactive04-0.1244-0.1158-0.0769-0.0272-0.0887-0.1244QC'd by "SIGMA"0
Inactive04-0.1459-0.077-0.0696-0.0992-0.1072-0.1459QC'd by "SIGMA"0
Inactive04-0.0112-0.12120.0729-0.0657-0.1082-0.0112QC'd by "SIGMA"0
Inactive04-0.0758-0.1319-0.0931-0.0564-0.0431-0.0758QC'd by "SIGMA"0
Inactive04-0.0061-0.0301-0.0049-0.0052-0.0205-0.0061QC'd by "SigmaAldrich"0
Inactive040.06630.0020.1992-0.0417-0.05850.0663QC'd by "SigmaAldrich"0
Inactive040.1620.0128-0.0595-0.0493-0.05030.162QC'd by "Interchem"0
Inactive04-0.0217-0.0781-0.08430.00810.004-0.0217QC'd by "SigmaAldrich"0
Inactive040-0.0307-1.0E-4-0.0089-0.03580QC'd by "SigmaAldrich"0
Inactive04-0.02990.0039-0.03650.0192-0.0786-0.0299QC'd by "SigmaAldrich"0
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:N/A
External ID: SPEC478CR
Protocol: Tox21 Assay Protocol Summary:

2,000 HepG2 cells in 5 uL of culture medium (MEM containing 10% FBS) per well were dispensed into black wall/clear bottom 1536-well plates using a Multidrop Combi Dispenser (ThermoFisher Scientific, Waltham, MA). The assay plates were incubated overnight at 37 C to allow cell attachment to the well bottom, followed by the transfer of 23 nL compound or DMSO vehicle by a pintool work station (Kalypsys , San Diego, CA). After the assay plates were incubated for 1 hr at 37 C and 5% CO2, fluorescence intensities in the assay plates were measured by an Envision (PerkinElmer, Shelton, CT) plate reader using three labels for measuring blue, green and red fluorescence at excitations 460, 535 and 590 nm respectively.
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent activators are ranked higher than compounds that showed apparent inhibition.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.

Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0005530000 uM-Replicate_1Activity at 0.00276 uM-Replicate_1Activity at 0.00765 uM-Replicate_1Activity at 0.012 uM-Replicate_1Activity at 0.024 uM-Replicate_1Activity at 0.034 uM-Replicate_1Activity at 0.074 uM-Replicate_1Activity at 0.148 uM-Replicate_1Activity at 0.199 uM-Replicate_1Activity at 0.370 uM-Replicate_1Activity at 0.743 uM-Replicate_1Activity at 1.207 uM-Replicate_1Activity at 1.859 uM-Replicate_1Activity at 3.722 uM-Replicate_1Activity at 9.170 uM-Replicate_1Activity at 13.42 uM-Replicate_1Activity at 18.62 uM-Replicate_1Activity at 45.97 uM-Replicate_1Activity at 91.34 uM-Replicate_1Activity at 95.67 uM-Replicate_1Activity at 202.9 uM-Replicate_1Activity at 354.0 uM-Replicate_1Activity at 920.3 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2Fit_InfiniteActivity-Replicate_2Fit_ZeroActivity-Replicate_2Fit_CurveClass-Replicate_2
Inactive04-0.77120.05930.0635-0.0984-0.218-0.7712QC'd by "Prestwick Chemical; Inc."0
Inactive040.28480.45950.13770.23990.45920.2848QC'd by "Prestwick Chemical; Inc."0
Inactive040.10910.08720.002-0.128-0.01040.1091QC'd by "Prestwick Chemical; Inc."0
Inactive040.35690.44360.30790.14920.38140.3569QC'd by "Prestwick Chemical; Inc."0
Inactive04-0.4718-0.21590.1141-0.2538-0.4782-0.4718QC'd by "Prestwick Chemical; Inc."0
Inactive04-0.7519-0.0052-0.0382-0.3499-0.5531-0.7519QC'd by "Prestwick Chemical; Inc."0
Inactive04-0.3026-0.176-0.2919-0.2217-0.1667-0.3026QC'd by "Prestwick Chemical; Inc."0
Inactive040.00260.10340.01420.20370.21520.0026QC'd by "Prestwick Chemical; Inc."0
Inactive04-0.309-0.54610.3903-0.3625-0.0293-0.309QC'd by "Prestwick Chemical; Inc."0
Inactive040.1015-0.23980.08980.41030.37930.1015QC'd by "Prestwick Chemical; Inc."0
Inactive04-0.02650.19180.1501-0.07350.0724-0.0265QC'd by "Prestwick Chemical; Inc."0
Inactive040.3519-0.54170.1370.20740.37870.3519QC'd by "Prestwick Chemical; Inc."0
Inactive040.11140.07490.32080.3560.48040.1114QC'd by "Prestwick Chemical; Inc."0
Inactive04-0.45320.0227-0.0204-0.4367-0.3391-0.4532QC'd by "Prestwick Chemical; Inc."0
Inactive04-0.4937-0.7632-0.0181-0.4913-0.1598-0.4937QC'd by "Prestwick Chemical; Inc."0
Inactive04-0.2868-0.3361-0.3349-0.465-0.3474-0.2868QC'd by "Prestwick Chemical; Inc."0
Inactive040.33880.03910.14580.56180.08170.3388QC'd by "Prestwick Chemical; Inc."0
Inactive040.5747-0.55850.02420.36260.57350.5747QC'd by "Prestwick Chemical; Inc."0
Inactive04-0.3048-0.2054-0.3202-0.3697-0.1434-0.3048QC'd by "Prestwick Chemical; Inc."0
Inactive04-0.27210.25420.1392-0.3556-0.4304-0.2721QC'd by "Prestwick Chemical; Inc."0
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:N/A
External ID: SPEC478CG
Protocol: Tox21 Assay Protocol Summary:

2,000 HepG2 cells in 5 uL of culture medium (MEM containing 10% FBS) per well were dispensed into black wall/clear bottom 1536-well plates using a Multidrop Combi Dispenser (ThermoFisher Scientific, Waltham, MA). The assay plates were incubated overnight at 37 C to allow cell attachment to the well bottom, followed by the transfer of 23 nL compound or DMSO vehicle by a pintool work station (Kalypsys , San Diego, CA). After the assay plates were incubated for 1 hr at 37 C and 5% CO2, fluorescence intensities in the assay plates were measured by an Envision (PerkinElmer, Shelton, CT) plate reader using three labels for measuring blue, green and red fluorescence at excitations 460, 535 and 590 nm respectively.
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent activators are ranked higher than compounds that showed apparent inhibition.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.

Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0005530000 uM-Replicate_1Activity at 0.00276 uM-Replicate_1Activity at 0.00765 uM-Replicate_1Activity at 0.012 uM-Replicate_1Activity at 0.024 uM-Replicate_1Activity at 0.034 uM-Replicate_1Activity at 0.074 uM-Replicate_1Activity at 0.148 uM-Replicate_1Activity at 0.199 uM-Replicate_1Activity at 0.370 uM-Replicate_1Activity at 0.743 uM-Replicate_1Activity at 1.207 uM-Replicate_1Activity at 1.859 uM-Replicate_1Activity at 3.722 uM-Replicate_1Activity at 9.170 uM-Replicate_1Activity at 13.42 uM-Replicate_1Activity at 18.62 uM-Replicate_1Activity at 45.97 uM-Replicate_1Activity at 91.34 uM-Replicate_1Activity at 95.67 uM-Replicate_1Activity at 202.9 uM-Replicate_1Activity at 354.0 uM-Replicate_1Activity at 920.3 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2Fit_InfiniteActivity-Replicate_2Fit_ZeroActivity-Replicate_2Fit_CurveClass-Replicate_2
Inactive04-0.0029-0.0082-0.00260.13990.0699-0.0029QC'd by "SIGMA"0
Inactive04-0.10090.004-0.1385-0.05520.0167-0.1009QC'd by "ChromaDex"0
Inactive04-0.00270.04690.0106-0.0323-0.0264-0.0027QC'd by "SIGMA"0
Inactive040.0680.04520.00930.1349-0.05650.068QC'd by "SigmaAldrich"0
Inactive04-0.01020.00830.0497-0.0368-0.1188-0.0102QC'd by "Sensient"0
Inactive040.16110.01260.0217-0.06560.10580.1611QC'd by "Pfaltz-Bauer"0
Inactive040.01860.00820.0242-0.11250.1760.0186QC'd by "SigmaAldrich"0
Inactive040.0141-0.0188-0.03030.00210.09840.0141QC'd by "SigmaAldrich"0
Inactive04-0.06960.0137-0.0094-0.0575-0.0122-0.0696QC'd by "SigmaAldrich"0
Inactive04-0.0879-0.00670.1326-0.0156-0.0041-0.0879QC'd by "SigmaAldrich"0
Inactive040.0162-0.0159-0.0079-0.01810.08710.0162QC'd by "SigmaAldrich"0
Inactive040.02930.0807-0.0391-0.1788-0.09160.0293QC'd by "SIGMA"0
Inactive04-0.0528-0.0224-0.08430.0049-0.0082-0.0528QC'd by "SIGMA"0
Inactive040.11520.05240.1778-0.0592-0.05560.1152QC'd by "SIGMA"0
Inactive04-0.03240.04210.01430.01780.0302-0.0324QC'd by "SIGMA"0
Inactive04-0.1527-0.0095-0.1287-0.0855-0.0912-0.1527QC'd by "SIGMA"0
Inactive040.1560.0209-0.00190.010.00660.156QC'd by "SIGMA"0
Inactive040.0052-0.00170.0141-0.07196.0E-40.0052QC'd by "SIGMA"0
Inactive04-0.0288-0.0779-0.0066-0.0587-0.0039-0.0288QC'd by "SIGMA"0
Inactive04-0.0014-0.08470.0444-0.017-0.0041-0.0014QC'd by "SigmaAldrich"0
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: HERG01
Protocol: NCGC Assay Protocol Summary:

HERG assay (FluxORTM thallium flux assay) was initially developed by Invitrogen/Molecular Probes, and then miniaturized into 1536-well plate in a homogeneous format by NCGC. This assay measures the activity of potassium channel using thallium dye (FluxOR) flux as surrogate measurement for potassium into the cells with a FDSS-7000 kinetic plate reader (Hamamatsu Corp., Hamamatsu City, Japan). The hERG ion channel is transduced into mammalian cells (U2OS) using a baculovirus (Bacmam) construct harboring the hERG K+ ion channel. So far we screened LOPAC1280 library (Sigma), the NTP collection of 1408 compounds, and the NCGC Pharmaceutical Collection (NPC), in which many well defined HERG blockers are present. The rank order potencies of many of these compounds are similar to that of other HERG assays (membrane potential, Rb+ flux, patch clamp, etc). This quick and homogeneous assay is also found to be sensitive, specific, and robust.

Using the FluxORTM thallium flux assay, the activity of potassium channel using thallium dye (FluxOR) flux as surrogate measurement for potassium into the cells was measured in the U2OS cell line transduced with hERG K+ ion channel using a baculovirus (Bacmam) using Opti-MEM medium (Invitrogen) containing 2% fetal calf serum (FCS, HyCone) following loading buffer addition, compound treatment for around 10 minutes and finally adding stimulation buffer. The assay was performed in black clear Kalypsys 1536-well plates. In the screen, Astemizole was used as positive controls. Library compounds were measured for their ability to cause hERG channel blockage in the cell line, as reflected by a decrease in fluorescence intensity, in a concentration-dependent manner. Data were normalized to the controls for basal activity (DMSO only) and 100% inhibition (5uM Astemizole). AC50 values were determined from concentration-response data modeled with the standard Hill equation.

qHTS protocol for hERG-U2OS cellular assay

[Step] [Parameter] [Value] [Description]

1. Day 1: Replace medium in 70-80% confluent T225 flask with 2.5 mL of hERG-BacMam virus plus 12.5 mL of phosphate buffered saline (PBS) (corresponding roughly to a multiplicity of infection ratio of 100 virus particles/cell)
2. Incubation: 4 hrs @ room Temperature in Dark
3. Reagent; Remove virus; wash once with 25 ml DPBS
4. Reagent; 35 ml culture medium
5. Incubation; 37oC overnight
6. Day2: Reagent; 3 uL; 2000 U2OS cells/well
7. Time; 4 hr; 37oC incubation
8. Loading buffer; 1 uL; 0.7X;
9. Incubation: 1hr @ RT in Dark.
10. Compounds; 23 nL; 0.59 nM to 92 uM
11. Controls; 23 nL; Astemizole 1.4 nM to 92 uM
12. Time; 10min; 37oC incubation
13. Read fluorescence Intensity on FDSS for 10 Sec with 1 sec interval
14. Reagent; 1 uL; stimulation buffer
15. Read fluorescence Intensity on FDSS for 2 min with 1 sec interval
16. Detection; Fluorescence Intensity; FDSS
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0001000000 uMActivity at 0.0003000000 uMActivity at 0.0006116734 uMActivity at 0.00133 uMActivity at 0.00297 uMActivity at 0.00673 uMActivity at 0.015 uMActivity at 0.033 uMActivity at 0.075 uMActivity at 0.167 uMActivity at 0.369 uMActivity at 0.412 uMActivity at 0.836 uMActivity at 1.842 uMActivity at 2.061 uMActivity at 4.179 uMActivity at 9.216 uMActivity at 20.61 uMActivity at 46.08 uMActivity at 92.17 uMCompound QC
Inactive04.0950.5622-0.5-17.405541 0 0 0 0 0 1 0 0 0 0 0 0 04.0358-8.1088-16.5879-0.7265-5.65844.3730.1327-9.70320.36854.1527-0.141-3.5272-0.9713-9.32034.0358QC'd by NIEHS/NTP
Activator15.848952.39750Single point of activity-4.80.40.510848.9806-3.416930 0 0 0 0 1 0 0 0 0 0 1 0 1 038.06212.0116-8.9739-7.06230-7.0944-39.2396018.733825.780800-59.539411.623748.215338.0621QC'd by NIEHS
Inactive04-1.0832-10.89741.0031-11.058-11.8883.65680.91825.31740.029-1.48932.17113.0788-19.8367-2.8584-1.0832QC'd by NIEHS/NTP
Inactive042.45982.223-1.63678.778-0.11389.22693.440711.6742-2.146511.8823-1.8078-2.0833.78254.49092.4598QC'd by NIEHS
Inactive01.85790.45754.5-21.089940 0 0 0 0 0 0 0 0 0 0 0 0 012.886-15.90830.10180.3771-0.02467.9993-3.79713.097311.63728.3022-2.66639.3202-2.3421-0.285412.886QC'd by NIEHS/NTP
Inactive04.95490.5492-6.77071.540 0 0 0 0 0 0 0 0 0 1 0 0 11.3669-1.0856-0.77651.12421.70580.7901-1.98696.09015.26593.2331-7.9279-28.3694-1.3017-10.22551.3669QC'd by NIEHS/NTP
Inactive04-5.5826-4.0359-4.4476-11.3473-11.9097-1.5507-10.1535-3.36261.3234-0.4426-13.9824-5.2512-18.0387-15.3022-5.5826QC'd by NIEHS/NTP
Inhibitor39.810751.900420Partial curve; partial efficacy-4.43.990.9828-50.13811.7623-2.20 0 0 0 0 0 0 0 0 0 0 0 0 0-49.45943.1993-0.02692.7134-1.98075.29460.2133-0.1387-0.26252.47080.17772.53720.4925-30.4729-49.4594QC'd by NIEHS/NTP
Inactive02.33320.6977-10.8456140 0 0 0 0 0 1 0 0 0 0 1 0 1-1.1266-1.46111.2528-0.03690.02955.5889-3.03576.75064.5747-1.4797-0.1821-9.6414-1.4402-9.8713-1.1266QC'd by NIEHS/NTP
Inactive0414.60080.5397-1.6708-0.4130.96947.4259-2.25855.08697.9351-2.4752-5.6365.39961.849-2.487114.6008QC'd by NIEHS/NTP
Inactive00.70.5791-8.9231440 0 0 0 0 0 1 0 0 0 0 0 0 12.80633.51535.19381.41166.33634.612.742912.44016.0481-0.14110.3707-1.47812.4968-5.76932.8063QC'd by NIEHS/NTP
Inactive04-17.8369-10.5115-2.5586-8.8158-26.0957-0.4819-9.7892-2.01490.27332.7166-17.2183-0.47591.0932-12.7028-17.8369QC'd by NIEHS/NTP
Inactive04.95490.4427-9.7222-1.541 0 1 0 0 0 0 0 0 0 0 0 0 0-13.1018-5.53920.00687.73370.45884.0455-12.3759-6.57240.92181.9145-11.3469-7.6261-8.5179-8.6226-13.1018QC'd by NIEHS/NTP
Inactive03.1320.7434-16.07841.540 0 0 0 0 0 0 0 0 0 0 0 0 13.99653.3921-1.15561.97152.01773.8894-2.6092.87572.72384.1025-3.54462.1635-3.6983-12.9823.9965QC'd by NIEHS/NTP
Inactive047.53724.3881-20.20115.5178-1.37582.0045-1.44014.9593-2.11221.3726-3.0011-3.06771.18832.18177.5372QC'd by NIEHS/NTP
Inactive0411.45250.2692-0.1403-0.3748-11.74892.8347-5.054616.89840.0513.829-3.6094-0.51978.0326-1.547611.4525QC'd by NIEHS/NTP
Inactive049.99361.71397.16916.3352-0.34329.148-5.8673-1.564112.6111.82378.2616-0.66541.73632.63199.9936QC'd by NIEHS/NTP
Inactive0410.2340.52521.3877-1.9626-0.9425.6494-0.276911.70528.3766.8657-0.149-0.19442.6788-6.419210.234QC'd by NIEHS/NTP
Activator22.387233.89380Complete curve; partial efficacy; poor fit-4.652.25260.715133.99630.10251.40 0 0 0 0 0 0 0 0 0 0 0 0 025.52240.4272-0.9219-0.128-2.10618.1765-1.5863-10.226512.16486.8628-0.3193-6.515517.608732.268925.5224QC'd by NIEHS/NTP
Inactive049.98485.58260.0396-1.5504-1.30043.2953.988212.27428.06469.11922.031.29227.4225-2.99749.9848QC'd by NIEHS/NTP
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:23209 靶标:N/A
External ID: UIHTS20180925
Protocol: Assay overview:
The purpose of this assay is to identify test compounds that differentially kill either epithelial cells or mesenchymal cells, critical components of EMT. The PC-3E+ and TEM4-18 cell lines, characterized as epithelial cells and mesenchymal cells respectively, were established in Henry Lab (Ref 1). For potential discriminative modulators of EMT, the two cells lines were labeled with GFP and mCherry respectively, and co-cultured together to eliminate those hits that non-discriminatingly kill both epithelial cells and mesenchymal cells by cytotoxicity irrelevant to the EMT properties.
Protocol for the EMT project:
The primary screening data were generated as described in HTS assay protocol table (Ref 2).

Table 1: HTS assay protocol table
Step Parameter Value Description
1. Plate cells 200 uL By MultiFlo. PC3E GFP 2,000 cells/ well and TEM418 mCherry 2,000 cells/well (1:1). Overnight incubation
2. Remove media Flip the plate
3. Add fresh media 150 uL By MultiFlo
4. Controls 200 uL C01-H01, C12 -H12, Hygromycin dose response from H to C were positive control. Wells A01, B01, A12 and B12 were negative control
5. Library 50 uL MSSP library 1 uM final from middle plate in full media
6. Incubation 72 hrs 37 C and 5% CO2
7. Assay readout GFP and mCherry channel imaging Perkin Elmer Operetta high content imaging system, with Harmony image analysis software.
8. Image analysis Green cells and Read cells counting Normalized to the average cell number of well B1 and B12 (no inhibition of cell viability) controls on each plate to get relative cell viability for each well.
9. Hit selection 11 hits The hit criteria for preferential cell killing are compounds that Redcells_Normalized is lower or equal 0.41, GreenCells_Normalized is higher or equal
0.55, RedCells/GreenCells_Normalized ratio is lower or equal 0.65, and Non-fluorescent by itself for Red cell killing OR Greencells_Normalized is
lower or equal 0.41, RedCells_Normalized is higher or equal 0.46, RedCells/GreenCells_Normalized ratio is higher or equal 1.8 and Non-fluorescent
by itself for Green cell killing.

The primary screening data (imaging data) were translated into Green or Red cell numbers in each well in the data file.
Comment: Preferential killing compounds are considered as active hits (score of 100) when meeting one of two groups of criteria:

1. Compounds that Redcells_Normalized is lower or equal 0.41, GreenCells_Normalized is higher or equal 0.55, RedCells/GreenCells_Normalized ratio is lower or equal 0.65, and Non-fluorescent by itself for Red cell killing.

OR

2. Greencells_Normalized is lower or equal 0.41, RedCells_Normalized is higher or equal 0.46, RedCells/GreenCells_Normalized ratio is higher or equal 1.8 and Non-fluorescent by itself for Green cell killing.
No. of GreenCellsNo. of RedCellsGreenCells_NormalizedRedCells_NormalizedRedCells/GreenCells_Normalized
178911800.881.081.22
196110810.970.991.02
187612910.931.181.27
224410941.1110.9
227512101.121.110.98
199513980.981.281.3
212312931.051.181.13
228112271.131.121
196410900.9711.03
211012951.041.181.14
234213611.161.241.08
201413160.991.21.21
2021127011.161.16
216012871.071.181.1
2022119711.091.1
179810820.890.991.11
193811991.081.060.98
200012601.121.110.99
197112011.11.060.96
210011301.1710.85
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:N/A
External ID: SPEC167CB
Protocol: Tox21 Assay Protocol Summary:

2,000 HEK293 cells in 5 uL of culture medium containing 10% dialyzed FBS per well were dispensed into black wall/clear bottom 1536-well plates using a Multidrop Combi Dispenser (Thermo Scientific). The assay plates were incubated for 4-5 hr at 37C to allow cell attachment to the well bottom, followed by the transfer of 23 nL compound or DMSO vehicle by a pintool work station (Kalypsys, San Diego, CA). After the assay plates were incubated overnight at 37C and 5% CO2, fluorescence intensities in the assay plates were measured by an Envision (PerkinElmer, Shelton, CT) plate reader using three labels for measuring blue, green and red fluorescence at excitations 460, 535 and 590nm respectively.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent activators are ranked higher than compounds that showed apparent inhibition.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0005530000 uM-Replicate_1Activity at 0.00276 uM-Replicate_1Activity at 0.00765 uM-Replicate_1Activity at 0.012 uM-Replicate_1Activity at 0.024 uM-Replicate_1Activity at 0.034 uM-Replicate_1Activity at 0.074 uM-Replicate_1Activity at 0.148 uM-Replicate_1Activity at 0.199 uM-Replicate_1Activity at 0.370 uM-Replicate_1Activity at 0.743 uM-Replicate_1Activity at 1.207 uM-Replicate_1Activity at 1.859 uM-Replicate_1Activity at 3.722 uM-Replicate_1Activity at 9.170 uM-Replicate_1Activity at 13.42 uM-Replicate_1Activity at 18.62 uM-Replicate_1Activity at 45.97 uM-Replicate_1Activity at 91.34 uM-Replicate_1Activity at 95.67 uM-Replicate_1Activity at 202.9 uM-Replicate_1Activity at 354.0 uM-Replicate_1Activity at 920.3 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2Fit_InfiniteActivity-Replicate_2Fit_ZeroActivity-Replicate_2Fit_CurveClass-Replicate_2
Inactive04-0.0993-0.0315-0.0456-0.0314-0.0445-0.0993QC'd by "SIGMA"0
Inactive04-0.0413-0.330.9732-0.1408-0.2626-0.0413QC'd by "SIGMA"0
Inactive043.0E-4-0.0951-0.0908-0.0608-0.01023.0E-4QC'd by "SIGMA"0
Inactive040.00362.0E-4-0.1154-0.1852-0.02580.0036QC'd by "SIGMA"0
Inactive04-0.08410.02920.0072-0.0606-0.0747-0.0841QC'd by "SIGMA"0
Inactive04-0.0562-0.02190.0027-0.0792-0.1435-0.0562QC'd by "SIGMA"0
Inactive04-0.0228-0.2225-0.17238.0E-4-0.2899-0.0228QC'd by "SIGMA"0
Inactive04-0.10910.0012-0.0968-0.007-0.2223-0.1091QC'd by "SIGMA"0
Inactive04-0.03890.07040.0162-0.0035-0.0387-0.0389QC'd by "SIGMA"0
Inactive040.0777-0.1888-0.0421-0.0179-0.13070.0777QC'd by "SIGMA"0
Inactive04-0.1076-0.1771-0.0039-0.04160.0041-0.1076QC'd by "SIGMA"0
Inactive04-0.0441-0.05340.0039-0.0433-0.1015-0.0441QC'd by "TCI"0
Inactive04-0.42250.18470.0082-0.0822-0.0703-0.4225QC'd by "SIGMA"0
Inactive040.0630.0914-0.00420.0899-0.04430.063QC'd by "SIGMA"0
Inactive040.21370.17290.0260.23310.10530.2137QC'd by "SIGMA"0
Inactive04-0.0274-0.01920.12090.04090.0156-0.0274QC'd by "SIGMA"0
Inactive040.0634-0.01480.0720.08030.08560.0634QC'd by "SIGMA"0
Inactive040.0335-0.04990.1012-0.00170.26310.0335QC'd by "SIGMA"0
Inactive04-0.0334-0.0211-0.0049-0.03310.19-0.0334QC'd by "SIGMA"0
Inactive040.15920.01470.11910.10190.12680.1592QC'd by "SIGMA"0
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:N/A
External ID: SPEC167CR
Protocol: Tox21 Assay Protocol Summary:

2,000 HEK293 cells in 5 uL of culture medium containing 10% dialyzed FBS per well were dispensed into black wall/clear bottom 1536-well plates using a Multidrop Combi Dispenser (Thermo Scientific). The assay plates were incubated for 4-5 hr at 37C to allow cell attachment to the well bottom, followed by the transfer of 23 nL compound or DMSO vehicle by a pintool work station (Kalypsys, San Diego, CA). After the assay plates were incubated overnight at 37C and 5% CO2, fluorescence intensities in the assay plates were measured by an Envision (PerkinElmer, Shelton, CT) plate reader using three labels for measuring blue, green and red fluorescence at excitations 460, 535 and 590nm respectively.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent activators are ranked higher than compounds that showed apparent inhibition.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0005530000 uM-Replicate_1Activity at 0.00276 uM-Replicate_1Activity at 0.00765 uM-Replicate_1Activity at 0.012 uM-Replicate_1Activity at 0.024 uM-Replicate_1Activity at 0.034 uM-Replicate_1Activity at 0.074 uM-Replicate_1Activity at 0.148 uM-Replicate_1Activity at 0.199 uM-Replicate_1Activity at 0.370 uM-Replicate_1Activity at 0.743 uM-Replicate_1Activity at 1.207 uM-Replicate_1Activity at 1.859 uM-Replicate_1Activity at 3.722 uM-Replicate_1Activity at 9.170 uM-Replicate_1Activity at 13.42 uM-Replicate_1Activity at 18.62 uM-Replicate_1Activity at 45.97 uM-Replicate_1Activity at 91.34 uM-Replicate_1Activity at 95.67 uM-Replicate_1Activity at 202.9 uM-Replicate_1Activity at 354.0 uM-Replicate_1Activity at 920.3 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2Fit_InfiniteActivity-Replicate_2Fit_ZeroActivity-Replicate_2Fit_CurveClass-Replicate_2
Inactive04-0.1742-0.0105-0.0707-0.708-0.8608-0.1742QC'd by "NCI"0
Inactive04-0.15950.087-0.0389-0.0424-0.0089-0.1595QC'd by "NCI"0
Inactive040.17150.56230.2590.06620.03240.1715QC'd by "NCI"0
Inactive040.04060.1038-4.0E-40.08940.12640.0406QC'd by "SigmaAldrich"0
Inactive040.439-0.1165-0.2370.53740.0650.439QC'd by "NCI"0
Inactive04-0.1787-0.0681-0.0763-0.05880.0674-0.1787QC'd by "NCI"0
Inactive04-0.26880.03020.2349-0.1201-0.1287-0.2688QC'd by "NCI"0
Inactive04-0.1086-0.2195-0.0573-0.14660.1358-0.1086QC'd by "NCI"0
Inactive04-0.1833-0.03-0.0379-0.4701-0.1431-0.1833QC'd by "NCI"0
Inactive04-0.9523-1.1611-0.9118-1.0013-1.0781-0.9523QC'd by "Labotest"0
Inactive04-0.2307-0.10680.4032-0.0433-0.0679-0.2307QC'd by "NCI"0
Inactive040.06170.30390.1775-0.00510.08570.0617QC'd by "NCI"0
Inactive04-0.1350.1614-0.083-0.1721-0.0432-0.135QC'd by "NCI"0
Inactive040.2214-0.6929-0.11650.0685-0.05560.2214QC'd by "NCI"0
Inactive04-0.2027-0.05290.0564-0.9701-0.3154-0.2027QC'd by "NCI"0
Inactive040.06990.0444-0.03810.03760.19960.0699QC'd by "NCI"0
Inactive040.0459-0.04550.12930.11980.02850.0459QC'd by "NCI"0
Inactive04-0.0306-0.0309-0.01430.02940.0175-0.0306QC'd by "Chembridge"0
Inactive04-0.02680.23620.2368-0.0791-0.0097-0.0268QC'd by "NCI"0
Inactive040.0114-0.9843-0.7454-0.13590.21030.0114QC'd by "NCI"0
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:
External ID: GRA481
Protocol: Tox21 Assay Protocol Summary:

The GR-bla HeLa cells were dispensed at 1500 cells/6 ul/well in 1536-well black wall/clear bottom plates using a Multidrop Combi (ThermoFisher Scientific, Waltham, MA) dispenser. After the assay plates were incubated at a 37 C/5% CO2 incubator for 4 hours, 23 nL of compounds dissolved in DMSO, positive controls or DMSO only was transferred to the assay plate by a pintool station (Kalypsys, San Diego, CA). The plates were incubated at 37 C for 18 hours. After 1 uL of LiveBLAzerTM B/G FRET substrate was added using a Flying Reagent Dispenser (Aurora Discovery, San Diego, CA), the plates were incubated at room temperature for 2 hours, and fluorescence intensity was measured by an Envision plate reader (PerkinElmer, Shelton, CT).
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent activators are ranked higher than compounds that showed apparent inhibition.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1W460-Activity_Score-Replicate_1W460-Curve_Description-Replicate_1W460-Fit_LogAC50-Replicate_1W460-Fit_HillSlope-Replicate_1W460-Fit_R2-Replicate_1W460-Fit_InfiniteActivity-Replicate_1W460-Fit_ZeroActivity-Replicate_1W460-Fit_CurveClass-Replicate_1W460-Excluded_Points-Replicate_1W460-Max_Response-Replicate_1W460-Activity at 0.0000036780 uM-Replicate_1W460-Activity at 0.0000082250 uM-Replicate_1W460-Activity at 0.0000183900 uM-Replicate_1W460-Activity at 0.0000514703 uM-Replicate_1W460-Activity at 0.0001157795 uM-Replicate_1W460-Activity at 0.0002347639 uM-Replicate_1W460-Activity at 0.0005064679 uM-Replicate_1W460-Activity at 0.00101 uM-Replicate_1W460-Activity at 0.00226 uM-Replicate_1W460-Activity at 0.00505 uM-Replicate_1W460-Activity at 0.011 uM-Replicate_1W460-Activity at 0.025 uM-Replicate_1W460-Activity at 0.056 uM-Replicate_1W460-Activity at 0.125 uM-Replicate_1W460-Activity at 0.280 uM-Replicate_1W460-Activity at 0.624 uM-Replicate_1W460-Activity at 1.391 uM-Replicate_1W460-Activity at 3.095 uM-Replicate_1W460-Activity at 6.900 uM-Replicate_1W460-Activity at 15.01 uM-Replicate_1W460-Activity at 29.18 uM-Replicate_1W460-Activity at 62.39 uM-Replicate_1W460-Activity at 79.15 uM-Replicate_1W460-Activity at 213.3 uM-Replicate_1W460-Activity at 765.1 uM-Replicate_1Ratio-Activity_Score-Replicate_1Ratio-Curve_Description-Replicate_1Ratio-Fit_LogAC50-Replicate_1Ratio-Fit_HillSlope-Replicate_1Ratio-Fit_R2-Replicate_1Ratio-Fit_InfiniteActivity-Replicate_1Ratio-Fit_ZeroActivity-Replicate_1Ratio-Fit_CurveClass-Replicate_1Ratio-Excluded_Points-Replicate_1Ratio-Max_Response-Replicate_1Ratio-Activity at 0.0000036780 uM-Replicate_1
Inactive040.7562-2.0191-2.8763-0.9026-3.551-0.7809-0.2770.3016-2.05597.6695-0.4571-0.4785-0.3067-3.19312.29950.7562102.72020.5091-13.21010.540 0 0 0 0 0 0 0 0 0 0 0 0 0 1-2.8015
Inconclusive2.683243.355504.95490.33697-1.259840 0 0 0 0 0 0 0 0 0 0 0 0 0 05.13651.0101-0.5652-4.3951-0.2458-3.9615-0.72250.0703-5.2165-4.71332.5855-0.82580.39810.8412-1.08125.1365103.06540.430911-0.15540 0 0 0 0 0 0 0 0 0 0 0 0 0 010.4779
Inactive00.9310.515-2.2498140 0 0 0 0 0 0 0 0 0 0 0 0 0 0-2.19170.0432-0.94582.66191.9187-0.00912.6540.7197-0.8071-0.0436-0.1456-2.86940.2333-3.1248-1.627-2.19171040.5349
Cytotoxic23.914564.59580Partial curve; partial efficacy-4.72133.1320.9596-43.45790.2745-2.20 0 0 0 0 0 0 0 0 0 0 0 0 0 0-39.3622.89331.82591.0907-0.1463-0.10590.92180.09150.19131.3078-6.7647-0.7119-0.62320.4675-17.992-39.362100.30.5041-9.1529140 0 0 0 0 0 0 0 0 0 0 0 0 0 13.6116
Inactive00.50.455-21.31571.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-14.42971.0157-1.7522.7232.69846.869-3.71430.19816.1321-2.0281-8.9254-4.3551-0.3757-5.1288-2.2826-14.4297100.20.470911.5-5.046140 0 0 0 0 0 0 0 0 0 0 0 0 0 1-2.922
Inconclusive15.08948.866903.51170.44866.5-1.011940 0 0 0 0 0 0 0 0 0 0 0 0 0 05.50351.07060.905-0.25830.69930.4392-0.1511-3.58922.2605-4.5752-0.49010.3402-2.2626-5.42666.35045.5035103.1320.5006-12.72791.540 0 0 0 0 0 0 0 0 0 0 0 0 0 1-0.019
Activator0.095244.78110Single point of activity-7.02134.95490.971588.6934-1.347630 0 0 0 0 0 0 0 1 1 1 1 1 1 1-0.2744-4.73250.61890.21280.81980.5686-0.35281.205386.9543-3.9984-3.1116-0.3361-4.4875-4.0498-7.4011-0.27440Single point of activity-7.02134.95490.969543.878-0.903130 0 0 0 0 0 0 0 1 1 1 1 1 1 1-0.1232
Inactive043.93180.3895-0.21130.182-0.9258-0.4412-3.95122.1721-0.1688-5.0997-0.15442.3995-4.165-0.19191.89093.9318104-1.6204
Inactive04.95490.4549-2.1971140 0 0 0 0 0 0 0 0 0 0 0 0 0 10.39480.2258-0.38513.3271.6718-0.0652.57751.6671-0.09210.011-0.24882.0368-2.0108-3.4976-0.2290.3948103.51170.49812-0.310640 0 0 0 0 0 0 0 0 0 0 0 0 0 1-0.5444
Inactive04.95490.49990.779540 0 0 0 0 0 0 0 0 0 0 0 0 0 07.19890.56481.7838-0.99043.56074.2105-1.85041.559-0.7889-0.57311.13450.3821.1458-0.6344-0.05567.19891043.2539
Inconclusive26.832542.156903.1320.6237-18.228140 0 0 0 0 0 0 0 0 0 0 0 0 0 0-14.8509-0.43261.3737-0.723-1.5954-0.98793.3248-0.25092.6333-1.3551-3.191.65445.081210.7255-16.44-14.85090Complete curve; partial efficacy; poor fit-5.32134.95490.903616-1.39761.40 0 0 0 0 0 0 0 0 0 0 0 0 1 014.2731
Inactive01.3310.44069-1.315540 0 0 0 0 0 0 0 0 0 0 0 0 0 07.7682-8.1796-1.2864-0.92690.0489-1.1023.6629-5.3855-2.0892-3.4173.63520.2376-0.11450.36824.02527.7682104.0950.645512.50.056140 0 0 0 0 0 0 0 0 0 0 0 0 0 013.4789
Inactive04-1.77665.9446-8.071110.9483-0.66150.7628-0.19420.81740.424-0.04970.3107-1.4675-4.3278-0.9634-3.4067-1.77661040.3915
Cytotoxic30.106580.09980Single point of activity-4.57134.95490.9233-34.1878-1-30 0 0 0 0 0 0 0 0 0 0 0 0 0 0-30.15651.4442-1.42590.5602-0.5727-1.5149-1.1531-1.7711-0.5991-1.6507-0.5856-0.7334-2.4262-6.8854-0.1814-30.15650Single point of activity-4.57134.95490.964133.76670.413730 0 0 0 0 0 0 0 0 0 0 0 0 0 0123.858
Inactive04.0950.6978-0.5-7.11540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-0.8355-7.1792-4.2685-1.14751.1488-2.8672-0.65330.9563-0.5809-0.63290.28570.6351.0765-3.2022-0.934-0.8355104.95490.8946-0.469515.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-2.4115
Inactive047.6683-0.213812.7411-0.95732.68175.82062.76031.9502-1.1272.6603-0.154-4.84897.2899-0.02820.21517.6683100.70.4452-6.3234340 0 0 0 0 0 0 0 0 0 0 0 0 0 1-1.9779
Inactive04.95490.38580-3.382540 0 0 0 0 0 0 0 0 0 0 0 0 0 00.3426-2.7245-4.1769-2.5201-5.3186-0.55251.2952-5.152-6.9854-0.68020.87571.22690.5227-3.0321.11160.3426104-1.3858
Inactive043.5373-0.4222-4.6002-0.5607-0.0671-0.45211.69491.7648-0.6170.1086-4.2139-4.41190.48912.0611-0.44833.5373104-0.2942
Activator10.682283.89470Single point of activity-4.97133.92950.884675.0549-2.701730 0 0 0 0 0 0 0 0 0 0 0 0 0 10.7587-0.7027-0.0356-2.9874-6.5873-2.95230.4426-0.8132-2.168-2.9385-0.9678-1.866-0.243-1.378889.35110.75870Single point of activity-4.97133.990.888280.6868-3.207930 0 0 0 0 0 0 0 0 0 0 0 0 0 10.0157
Inactive043.2274-0.4217-5.36674.2879-0.76117.993-0.6172-2.95230.12040.2389-2.49690.367-2.94147.0059-0.88663.2274103.06540.600216-1.455840 0 0 0 0 0 0 0 0 0 0 0 0 0 15.6692
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:The Scripps Research Institute Molecular Screening Center 靶标:N/A
External ID: FBW7_ACT_ALPHA_1536_1X%ACT PRUN
Protocol: Assay Overview:
FBW7 assay principle. In this assay, either mutant or wild type (w.t.) FBW7 interact with phosphorylated cyclin E peptide (cycE~P), which will bring donor and acceptor beads into close proximity. Laser excitation of the donor beads converts oxygen to an excited singlet state. Reaction of the singlet oxygen with the acceptor beads further activates a chemiluminescence/fluorescence reaction within the same bead resulting in emitted light at 520-620 nm. Small molecule activators that enhance the mutant FBW7 interaction with the cycE~P decrease the distance of the acceptor beads, thus leading to increased signal being emitted signal.
Protocol Summary:
There are six steps in this 1536 well assay format which are listed in order. First, 2.5uL/well of a 2X working solution containing RLFbw7 [12.5nM final], Cyclin E peptide [12.5nM final], and Ni beads [5ug/mL final], in assay buffer (25mM Tris-HCl pH 7.4 + 100mM NaCl, 0.1% Tween-20, 5mM ?-Mercaptoethanol and 0.05% BSA) was dispensed into columns 1-44. Then 2.5uL/well of a 2X working solution containing WTFbw7 [12.5nM final], Cyclin E peptide [12.5nM final], and Ni beads [5ug/mL final], in assay buffer was dispensed into columns 45-48. Using the pintool transfer device 134nL of compound or control was added to each well. This achieved a nominal screening concentration of 26.1uM and 2.6% DMSO concentration. This was followed by the addition of SA beads to all wells at 5ug/mL final concentration in assay buffer. The assay was then incubated for 20 hours in a temperature controlled 25C environment followed by Alphascreen detection using the PerkinElmer EnVision.

The percent activation for each compound was calculated as follows:

100 *( ( Test_Compound - Median_Low_Control ) / ( Median_High_Control - Median_Low_Control ) )
Where:
Test_Compound is defined as wells containing RLFbw7 (mutant), cyclin E peptide and Nickel acceptor beads in the presence of test compound
High_Control is defined as wells containing WTFbw7 (wild type), cyclin E peptide and Nickel acceptor beads
Low_Control is defined as the median of the wells containing DMSO, RLFbw7 (mutant), cyclin E peptide and Nickel acceptor beads
PubChem Activity Outcome and Score:

A mathematical algorithm was used to determine active compounds. Two values were calculated: (1) the average percent activation of all compounds tested for the screen, and (2) three times their standard deviation. The sum of these two values was used as a cutoff parameter, i.e. any compound that exhibited greater percent activation than the cutoff parameter (1.85% in the case here) was declared active.
The reported PubChem Activity Score has been normalized to 100% observed primary inhibition. Negative % inhibition values are reported as activity score zero.
The activity score range for active compounds is 100-1, for inactive 1-0.
List of Reagents:
Ni Beads- PerkinEmer Lifesciences Cat#6760619R
RLFbw7-Assay Provider
WTFbw7-Assay Provider
Cyclin E peptide-Assay Provider
5M NaCl- Sigma Cat# S6546-1L
Tween20- Fisher Cat# BP337
Tris 1M pH7.4 Research Organics Cat# 9686T
BSA-Sigma Cat#A7030
?-Mercaptoethanol-SigmaM6250
1536-well plates (Corning, part 7254)
Comment: Due to the size of the Scripps Molecular Screening Center compound library, this assay may have been run as two or more separate campaigns, each campaign testing a unique set of compounds. All data reported were normalized on a per-plate basis. Possible artifacts of this assay can include, but are not limited to: dust or lint located in or on wells of the microtiter plate, compounds that modulate well fluorescence. All test compound concentrations reported above and below are nominal; the specific test concentration(s) for a particular compound may vary based upon the actual sample provided by the Scripps Molecular Screening Center.
Inhibition at 26.1 uM
1.22
1.22
1.22
1.22
1.21
1.21
1.21
1.21
1.21
1.21
1.21
1.21
1.21
1.21
1.21
1.21
1.21
1.21
1.21
1.21
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:
External ID: GRN257
Protocol: Tox21 Assay Protocol Summary:

The GR-bla HeLa cells were dispensed at 1500 cells/5 ul/well in 1536-well black wall/clear bottom plates using a Multidrop Combi (ThermoFisher Scientific, Waltham, MA) dispenser. After the assay plates were incubated at a 37 C/5% CO2 incubator for 4 hours, 23 nL of compounds dissolved in DMSO, positive controls or DMSO only was transferred to the assay plate by a pintool station (Kalypsys, San Diego, CA), followed by addition of 1 uL of dexamethasone (5 nM, final concentration in the well). The plates were incubated at 37 C for 18 hours. After 1 uL of LiveBLAzerTM B/G FRET substrate was added using a Flying Reagent Dispenser (Aurora Discovery, San Diego, CA), the plates were incubated at room temperature for 2 hours, and fluorescence intensity was measured by an Envision plate reader (PerkinElmer, Shelton, CT).
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1W460-Activity_Score-Replicate_1W460-Curve_Description-Replicate_1W460-Fit_LogAC50-Replicate_1W460-Fit_HillSlope-Replicate_1W460-Fit_R2-Replicate_1W460-Fit_InfiniteActivity-Replicate_1W460-Fit_ZeroActivity-Replicate_1W460-Fit_CurveClass-Replicate_1W460-Excluded_Points-Replicate_1W460-Max_Response-Replicate_1W460-Activity at 0.0000036780 uM-Replicate_1W460-Activity at 0.0000082250 uM-Replicate_1W460-Activity at 0.0000183900 uM-Replicate_1W460-Activity at 0.0000514202 uM-Replicate_1W460-Activity at 0.0001158387 uM-Replicate_1W460-Activity at 0.0002261535 uM-Replicate_1W460-Activity at 0.0004949824 uM-Replicate_1W460-Activity at 0.00102 uM-Replicate_1W460-Activity at 0.00229 uM-Replicate_1W460-Activity at 0.00510 uM-Replicate_1W460-Activity at 0.011 uM-Replicate_1W460-Activity at 0.025 uM-Replicate_1W460-Activity at 0.057 uM-Replicate_1W460-Activity at 0.127 uM-Replicate_1W460-Activity at 0.284 uM-Replicate_1W460-Activity at 0.634 uM-Replicate_1W460-Activity at 1.415 uM-Replicate_1W460-Activity at 3.154 uM-Replicate_1W460-Activity at 7.040 uM-Replicate_1W460-Activity at 15.11 uM-Replicate_1W460-Activity at 27.01 uM-Replicate_1W460-Activity at 58.48 uM-Replicate_1W460-Activity at 78.95 uM-Replicate_1W460-Activity at 216.1 uM-Replicate_1W460-Activity at 765.1 uM-Replicate_1Ratio-Activity_Score-Replicate_1Ratio-Curve_Description-Replicate_1Ratio-Fit_LogAC50-Replicate_1Ratio-Fit_HillSlope-Replicate_1Ratio-Fit_R2-Replicate_1Ratio-Fit_InfiniteActivity-Replicate_1Ratio-Fit_ZeroActivity-Replicate_1Ratio-Fit_CurveClass-Replicate_1Ratio-Excluded_Points-Replicate_1Ratio-Max_Response-Replicate_1Ratio-Activity at 0.0000036780 uM-Replicate_1
Inactive04-12.097-15.4211.22518.50446.32020.846114.98991.67820.3453-2.12172.5147-17.8498-9.32760.28162.6709-12.097104-12.0519
Inconclusive0Single point of activity-4.52134.95490.372839.41940.385430 0 0 0 0 0 0 0 0 0 0 0 0 0 032.79711.95395.33912.21820.80081.884415.32420.02920.8207-21.1398-1.4369-24.04185.752217.14520.630832.79711040.9716
Inactive04-5.25290.17872.973832.766221.31856.600616.055125.63979.842634.3918-9.8497-0.1044-5.717114.7663-0.7047-5.25291046.6113
Cytotoxic23.914544.75320Partial curve; high efficacy-4.77133.06540.9397-151.36460.7993-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-140.15255.712-11.72013.174311.80043.9627-11.745919.69894.1037-4.89243.0574-21.16290.0911-4.4585-74.4823-140.15250Complete curve; high efficacy-4.97133.51170.8761-65.1981-0.3709-1.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-64.7954
Inhibitor26.8325102.2380Single point of activity-4.57134.95490.7068-122.91268.4508-30 0 0 0 0 0 0 0 0 0 0 0 0 0 0-103.83561.9814-8.2905-0.6801-2.507810.7911-7.456524.81948.5806-7.33822.7627-1.146220.661865.1802-2.288-103.83560Single point of activity-4.57134.95490.8259-97.04015.198-30 0 0 0 0 0 0 0 0 0 0 0 0 0 0-85.6797
Inactive043.352-18.3617-0.7198-1.82120.7254-2.3887-0.71138.1346-18.636610.8874-1.88711.636-16.58518.3351-18.83343.3521042.0179
Inconclusive0Complete curve; partial efficacy; poor fit-7.52131.46410.680236.20112.51.41 0 0 0 0 0 0 0 0 0 1 1 1 1 122.057130.60393.688701.975524.92820.940436.70837.549926.490437.73945.076219.601119.7132-3.264822.0571104-2.2828
Inactive043.5852-0.9953.1779-2.90782.9481-0.79636.8681-22.0598-14.2108-2.2977-16.3346-2.03172.00522.18690.90223.5852104-2.9287
Inactive04-2.74024.46784.162900.150523.553338.24690.453-5.2560.55339.8796-0.6274-4.2999023.1032-2.7402104-6.1592
Inactive0417.07540.24292.78673.44132.792-1.4151.419821.8245-2.16183.6162-18.04260.0956-1.3056-2.398512.358417.0754104-11.8022
Cytotoxic26.832542.81820Single point of activity-4.57134.95490.9428-140.4676.5416-30 0 0 0 0 0 0 0 0 0 0 0 0 0 0-123.21672.731110.1203-0.9412-0.006715.33822.152318.6872.49431.3665-0.576414.2545-2.3685-1.0992-1.3076-123.21670Partial curve; partial efficacy; poor fit-4.52130.60.588-65.2178-6.1658-2.40 0 0 0 0 0 0 0 0 0 0 0 0 0 0-51.7601
Inconclusive0Partial curve; partial efficacy-4.92131.10.711641.11172.152.20 0 0 0 0 0 0 0 0 0 0 0 0 0 040.5279-2.658815.3997-1.32051.54133.8511.1616-0.54452.66480.16530.4079-0.475322.922612.925317.4440.5279104-1.1211
Inactive045.3983-14.35172.32162.82171.398410.6583-13.337-1.73434.042716.340518.8055-0.856912.351214.0297-4.28015.3983104-15.3874
Cytotoxic26.832560.9510Single point of activity-4.57134.95490.8965-166.924610.764-30 0 0 0 0 0 0 0 0 0 0 0 0 0 0-155.4129-4.74481.248714.33939.9359-5.64392.083840.29660.993714.79787.97237.785523.56762.329620.0585-155.41290Single point of activity-4.57134.95490.72-34.1482.3048-30 0 0 0 0 0 0 0 0 0 0 0 0 0 0-30.286
Inactive04-17.9221-5.6935-9.7378-15.0242-13.45874.1955-20.9421.6642.78496.2808-1.65063.6358-21.3152-1.5804-17.7116-17.9221104-3.4006
Inactive04-16.0736-0.16670.063414.39452.22271.76036.0139-16.78778.30026.13620.2785-23.70580.041617.93561.9071-16.0736104-0.4858
Inactive00.70.515419.5726-16.145540 0 0 0 0 0 1 0 0 0 0 0 0 0 1-18.9267-14.0001-14.1391-15.825-18.1982-31.1347-5.992124.7447-16.7843-1.0696-18.5346-4.5707-4.9181-7.002213.1558-18.9267104-7.4051
Inactive04-15.437230.19180.87326.82955.19737.68435.82839.8057-1.3433-0.6271-0.7496-16.36081.435420.67980.2025-15.43721040.541
Inactive04-8.09546.20142.679-3.15441.45620.91-3.2719-6.17514.4834-9.2058-3.6067-5.2067-7.29356.5535-11.4671-8.0954104-19.5741
Inconclusive04-6.5078-13.7847-11.6608-0.2953-62.2272-22.8473-5.7475-4.5773-29.0585-18.6043-33.5711-11.69590-23.5243-23.2348-6.50780Single point of activity-4.57134.95490.701639.7004-8.651930 0 0 0 0 0 0 0 0 0 0 0 0 0 036.4575
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:N/A
External ID: GRV193
Protocol: Tox21 Assay Protocol Summary:

The GR-bla HeLa cells were dispensed at 1500 cells/5 ul/well in 1536-well black wall/clear bottom plates using a Multidrop Combi (ThermoFisher Scientific, Waltham, MA) dispenser. After the assay plates were incubated at a 37 C/5% CO2 incubator for 4 hours, 23 nL of compounds dissolved in DMSO, positive controls or DMSO only was transferred to the assay plate by a pintool station (Kalypsys, San Diego, CA), followed by addition of 1 uL of dexamethasone (5 nM, final concentration in the well). The plates were incubated at 37 C for 18 hours. After 1 uL of LiveBLAzerTM B/G FRET substrate was added using a Flying Reagent Dispenser (Aurora Discovery, San Diego, CA), the plates were incubated at room temperature (RT) for 2 hours, and fluorescence intensity was measured by an Envision plate reader (PerkinElmer, Shelton, CT). After measurement of bla assay, 3 ul CellTiter-Glo (Promega, Madison, WI) was added to measure the cytotoxicity and the plates were then incubated at RT for 30 min. The luminescence was measured using a ViewLux (Perkin Elmer) plate reader.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000036780 uM-Replicate_1Activity at 0.0000082250 uM-Replicate_1Activity at 0.0000183900 uM-Replicate_1Activity at 0.0000514202 uM-Replicate_1Activity at 0.0001156673 uM-Replicate_1Activity at 0.0002261535 uM-Replicate_1Activity at 0.0004949824 uM-Replicate_1Activity at 0.00102 uM-Replicate_1Activity at 0.00229 uM-Replicate_1Activity at 0.00510 uM-Replicate_1Activity at 0.011 uM-Replicate_1Activity at 0.025 uM-Replicate_1Activity at 0.057 uM-Replicate_1Activity at 0.127 uM-Replicate_1Activity at 0.284 uM-Replicate_1Activity at 0.634 uM-Replicate_1Activity at 1.415 uM-Replicate_1Activity at 3.154 uM-Replicate_1Activity at 7.040 uM-Replicate_1Activity at 15.11 uM-Replicate_1Activity at 27.01 uM-Replicate_1Activity at 58.48 uM-Replicate_1Activity at 78.95 uM-Replicate_1Activity at 216.1 uM-Replicate_1Activity at 765.1 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2Fit_InfiniteActivity-Replicate_2
Inactive04-8.9896-7.3975-6.7113-14.8241-4.5178-1.517512.264-8.1607-13.49270.92690.0472-1.09210.2383-2.6378-1.9489-8.9896QC'd by SequoiaCytotoxic0.006727.901520Complete curve; partial efficacy; poor fit-8.17134.95490.4115-26.6818
Inactive04-12.8644-12.4335-6.4744-20.0821-10.89713.6433-6.8703-5.7214-9.84543.7236-7.371-2.7049-10.4097-16.8792-5.8495-12.8644QC'd by FLUKAInactive0
Inactive00.60.6935-5.705513.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-2.93149.184113.869-0.63448.33090.23784.4977-4.6175-6.73290.5376-2.5323-8.0879-5.8972-4.0555-7.5668-2.9314QC'd by FLUKACytotoxic47.715650.274420Partial curve; partial efficacy; poor fit-4.32130.30.4501-54.3952
Inactive0412.0884-2.3949-3.4828-3.133815.632524.520517.03-4.6009-4.4756-1.6879.12462.7279-2.11843.193-0.18912.0884QC'd by BIOMOLInconclusive1.068269.039710Partial curve; partial efficacy; poor fit-5.97130.20.438955.7277
Cytotoxic26.832573.745320Single point of activity-4.57134.95490.8323-69.69384.0515-30 0 0 0 0 0 0 0 0 0 0 0 0 0 0-61.368517.6007-1.759413.0949-3.274312.563612.30281.95770.648-6.95350.28381.5448-0.0522-1.42575.7042-61.3685QC'd by BIOMOLCytotoxic21.313893.273741Partial curve; high efficacy-4.67132.90230.9235-86.9043
Inactive046.7909-1.31027.7383-4.547-2.65212.1059-2.4181-1.10118.09747.2420.3477-5.05879.40029.3931-0.87996.7909QC'd by BIOMOLInactive0
Inactive041.4423-3.99322.77927.1221-0.8837-8.95352.295-0.51041.37322.285720.59571.5207-5.3744.2397-11.91461.4423QC'd by BIOMOLInactive0
Inactive00.60.3367-9.79324.540 0 0 0 0 0 0 0 0 0 0 0 0 0 12.02261.3465-0.45472.410510.291411.99868.0638-8.1616.00951.6819-2.0122-2.01511.6093-6.3684-6.20422.0226QC'd by BIOMOLInactive02.47290.378538.7776
Inactive0415.2343-1.80842.058715.92577.90848.0244-2.30815.36692.48331.03819.9575-3.366-5.2227-2.2446-0.160715.2343QC'd by BIOMOLInactive0
Inactive047.9538-1.872810.9648-1.09872.6071-1.078614.35211.0497-1.76951.8577-2.7126-2.4267-0.2948-1.380911.52387.9538QC'd by BIOMOLInconclusive18.995953.670810Partial curve; partial efficacy; poor fit-4.72132.40640.570554.7236
Inactive04.95490.518517.50.289140 0 0 0 0 0 0 0 0 0 0 0 0 0 013.283514.4715-2.8018-2.2504-1.854-1.0751.91726.8822-1.1544-5.5924-0.0354-3.34427.78934.034525.595213.2835QC'd by BIOMOLInactive0
Inactive049.45185.1439-10.9187-3.6004-4.60710.015617.848513.801-6.53560.5436-3.981315.85290.99558.7778-0.51489.4518QC'd by BIOMOLInconclusive0.169342.502710Single point of activity-6.77133.92950.653739.4606
Inactive041.8471-10.88334.52062.79765.23563.9098-5.1881-2.0961-0.0954-3.919-3.2093-1.8064-33.7228-4.1242-0.88821.8471QC'd by BIOMOLInactive04.95490.31142.5
Inactive044.8349-4.63776.5338-3.86720.3182-6.07670.8186-2.79026.0128-0.779714.731111.52557.4133-0.9249-2.93594.8349QC'd by BIOMOLInactive04.95490.371213.3777
Inactive04-4.067912.1355-8.423722.677520.0333.0761-4.23854.78041.17568.42751.9834-7.49172.3009-2.1910.399-4.0679QC'd by BIOMOLInconclusive0.016923.312910Complete curve; partial efficacy; poor fit-7.77134.95490.334218.2886
Inactive042.05745.26574.3417-5.6188-2.5518-0.73413.2906-1.1924-0.81874.4295-6.552710.0188-0.8658-4.17642.45482.0574QC'd by BIOMOLInactive0
Inactive048.5616-2.0682-0.46498.21222.20687.6990.2449-0.087712.19887.0464-0.3008-1.4858-2.93310.76220.39078.5616QC'd by BIOMOLInactive0
Cytotoxic6.00796.604783Complete curve; high efficacy-5.22134.95490.9827-93.96262.6422-1.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-96.07621.3064-6.14065.13090.1256-0.83290.3014-0.60629.61044.55867.1299-0.84948.1454-69.6407-92.7982-96.0762QC'd by BIOMOLCytotoxic5.353889.607684Complete curve; high efficacy-5.27134.95490.9148-95.5166
Inactive04-3.2987-4.8177-8.49767.47813.7599.2959-2.2766-1.27941.7611-5.167216.38672.699710.28948.2038-9.5775-3.2987QC'd by BIOMOLInconclusive0.030119.213610Complete curve; partial efficacy; poor fit-7.52134.95490.332612.8869
Inactive048.7339-1.21470.07750.0749-2.3291-0.54618.96933.3015-2.1752-15.4981-13.43471.2297-0.91132.62215.99288.7339QC'd by BIOMOLInactive0
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Macrophage migration inhibitory factor
External ID: CHEMBL5133036
Protocol: N/A
Comment: Journal: Bioorg Med Chem Lett
Year: 2022
Volume: 55
First Page: 128445
Last Page: 128445
DOI: 10.1016/j.bmcl.2021.128445

Target ChEMBL ID: CHEMBL2085
ChEMBL Target Name: Macrophage migration inhibitory factor
ChEMBL Target Type: SINGLE PROTEIN - Target is a single protein chain
Relationship Type: D - Direct protein target assigned
Confidence: Direct single protein target assigned
Standard TypeStandard UnitsActivity Comment
Inhibition%Active
Inhibition%Active
Inhibition%Active
Inhibition%Active
Inhibition%Active
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:i-motif DNA
External ID: CHEMBL5105694
Protocol: N/A
Comment: Journal: Bioorg Med Chem Lett
Year: 2022
Volume: 73
First Page: 128886
Last Page: 128886
DOI: 10.1016/j.bmcl.2022.128886

Target ChEMBL ID: CHEMBL4845622
ChEMBL Target Name: i-motif DNA
ChEMBL Target Type: NUCLEIC-ACID - Target is DNA, RNA or PNA
Relationship Type: M - Molecular target other than protein assigned
Confidence: Target assigned is molecular non-protein target
Standard TypeStandard RelationStandard ValueStandard Units
Delta Tm=-3.7degrees C
Delta Tm=-3.9degrees C
Delta Tm=0degrees C
Delta Tm=-5.4degrees C
Delta Tm=-2.5degrees C
Delta Tm=-1.8degrees C
Delta Tm=-6.4degrees C
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:i-motif DNA
External ID: CHEMBL5105695
Protocol: N/A
Comment: Journal: Bioorg Med Chem Lett
Year: 2022
Volume: 73
First Page: 128886
Last Page: 128886
DOI: 10.1016/j.bmcl.2022.128886

Target ChEMBL ID: CHEMBL4845622
ChEMBL Target Name: i-motif DNA
ChEMBL Target Type: NUCLEIC-ACID - Target is DNA, RNA or PNA
Relationship Type: M - Molecular target other than protein assigned
Confidence: Target assigned is molecular non-protein target
Standard TypeStandard RelationStandard ValueStandard Units
Delta Tm=-0.4degrees C
Delta Tm=-0.4degrees C
Delta Tm=-0.3degrees C
Delta Tm=-0.8degrees C
Delta Tm=-0.5degrees C
Delta Tm=-0.5degrees C
Delta Tm=-0.4degrees C
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:quadruplex DNA
External ID: CHEMBL5105696
Protocol: N/A
Comment: Journal: Bioorg Med Chem Lett
Year: 2022
Volume: 73
First Page: 128886
Last Page: 128886
DOI: 10.1016/j.bmcl.2022.128886

Target ChEMBL ID: CHEMBL3832742
ChEMBL Target Name: quadruplex DNA
ChEMBL Target Type: NUCLEIC-ACID - Target is DNA, RNA or PNA
Relationship Type: M - Molecular target other than protein assigned
Confidence: Target assigned is molecular non-protein target
Standard TypeStandard RelationStandard ValueStandard Units
Delta Tm=-4.6degrees C
Delta Tm=-3.8degrees C
Delta Tm=-1.8degrees C
Delta Tm=-4.7degrees C
Delta Tm=-3.6degrees C
Delta Tm=-2.9degrees C
Delta Tm=-2.4degrees C
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:i-motif DNA
External ID: CHEMBL5105697
Protocol: N/A
Comment: Journal: Bioorg Med Chem Lett
Year: 2022
Volume: 73
First Page: 128886
Last Page: 128886
DOI: 10.1016/j.bmcl.2022.128886

Target ChEMBL ID: CHEMBL4845622
ChEMBL Target Name: i-motif DNA
ChEMBL Target Type: NUCLEIC-ACID - Target is DNA, RNA or PNA
Relationship Type: M - Molecular target other than protein assigned
Confidence: Target assigned is molecular non-protein target
Standard TypeStandard RelationStandard ValueStandard Units
Delta Tm=-2.7degrees C
Delta Tm=-2.6degrees C
Delta Tm=-2.4degrees C
Delta Tm=-2.4degrees C
Delta Tm=-2.2degrees C
Delta Tm=-1.8degrees C
Delta Tm=-2.6degrees C
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:N/A
External ID: PLD386
Protocol: Assay Protocol Summary:

HepG2 cells are dispensed at 900 cells/3 uL/well into Collagen I-coated 1536-well black-wall/clear-bottom assay plates (Greiner Bio-One, Monroe, NC) using the Multidrop Combi 8 channel dispenser (Thermo Fisher, Waltham, MA, USA). The assay plates are incubated at 37 C for 4 hours to allow the cell attachment. 3 uL of 1:500 LipidTOX Red dye is added using the dispenser, and then 23 nL compounds are added via a Wako Pintool station (Wako Automation, San Diego, CA). Amiodarone, a known PLD inducer, was used as a positive control and DMSO was used as a negative control. The assay plates were then incubated at 37 C for 24 hours.

For fixations, 4 uL of 8% paraformaldehyde fixative solution containing 10 ug/mL Hoechst 33342 in Dulbecco's phosphate-buffered saline (DPBS) is added using a Kalypsys washer/dispenser (Kalypsys, San Diego, CA, USA). After incubation at room temperature for 30 min, the assay plates are washed once with DPBS using a Kalypsys washer/dispenser. The assay plates are then sealed and stored at 4 C before imaging. The fluorescence intensities (595 nm excitation, 615 nm emission for LipidTOX; 352 nm excitation, 461 nm emission for Hoechst 33342) are measured using an ImageXpress Micro Widefield High Content Screening System (Molecular Devices, Sunnyvale, CA, USA) with a 20x Plan Fluor objective. Images are acquired for one site in each well and analyzed with the MetaXpress software (Molecular Devices) using the Transfluor module. Several algorithmic outputs, such as pit count per well, pit count per cell, pit integrated intensity per well, and pit integrated intensity per cell, are used for quantitative image analysis for PLD.
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent activators are ranked higher than compounds that showed apparent inhibition.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.00123 uMActivity at 0.00559 uMActivity at 0.012 uMActivity at 0.025 uMActivity at 0.039 uMActivity at 0.059 uMActivity at 0.137 uMActivity at 0.153 uMActivity at 0.306 uMActivity at 0.612 uMActivity at 0.710 uMActivity at 1.532 uMActivity at 3.148 uMActivity at 4.894 uMActivity at 7.662 uMActivity at 15.53 uMActivity at 19.04 uMActivity at 38.30 uMActivity at 69.89 uMActivity at 78.45 uMActivity at 150.9 uMActivity at 192.2 uMCompound QC
Inactive040.52250.9197-0.2148-3.0798-0.7670.5225QC'd by NCI
Inactive04.95490.8575-2.5047240 0 0 0 0-1.01231.96521.94551.9624-3.7539-1.0123QC'd by NCI
Inactive03.92950.83390.0205640 0 0 0 0-0.59373.8164-1.23290.78590.4134-0.5937QC'd by NCI
Inactive040.409-0.922-0.3836-0.40790.28520.409QC'd by SigmaAldrich
Inactive01.210.57212.5-3.682440 0 0 0 02.3849-1.4022.82760.22324.62172.3849QC'd by NCI
Inactive044.1808-1.330312.1123-1.67094.93474.1808QC'd by NCI
Inactive04-0.1837-0.95772.373-1.54381.4476-0.1837QC'd by NCI
Inactive040.46912.01460.25580.34690.4350.4691QC'd by NCI
Inactive04.50450.94036-0.886640 0 0 0 05.8940.1078-1.9889-1.3913-0.60335.894QC'd by NCI
Activator28.183821.270410Partial curve; partial efficacy; poor fit-4.554.95490.994720.5-0.77042.40 0 0 0 016.7877-1.4632-0.6573-0.2313-1.475416.7877QC'd by Labotest
Inactive04-0.1246-1.73481.1946-0.6236-2.6757-0.1246QC'd by NCI
Inactive04-1.78780.0388-2.7225-2.2048-3.4121-1.7878QC'd by NCI
Inactive04.95490.7197-1.20362.540 0 0 0 0-0.44512.63960.68823.5768-2.253-0.4451QC'd by NCI
Activator8.912523.358910Partial curve; partial efficacy; poor fit-5.053.06540.991522-1.35892.40 0 0 0 021.82270.1626-2.3824-1.40577.419521.8227QC'd by NCI
Inactive041.0997-1.7227-0.835.0E-4-0.03191.0997QC'd by NCI
Inactive044.0416-0.1081-0.36380.1442-0.67394.0416QC'd by NCI
Inactive01.06410.9939-6.19520.540 0 0 0 11.19570.784-0.0956-1.6108-4.32931.1957QC'd by NCI
Inactive04-0.2978-0.07670.61.2943-0.2232-0.2978QC'd by Chembridge
Inactive041.282-0.3951-1.4501-0.0311-2.36261.282QC'd by NCI
Inactive02.40640.31175-240 0 0 0 07.0020.90276.95040.35115.08377.002QC'd by NCI
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:RAW264.7
External ID: CHEMBL5133032
Protocol: N/A
Comment: Journal: Bioorg Med Chem Lett
Year: 2022
Volume: 55
First Page: 128445
Last Page: 128445
DOI: 10.1016/j.bmcl.2021.128445

Target ChEMBL ID: CHEMBL612557
ChEMBL Target Name: RAW264.7
ChEMBL Target Type: CELL-LINE - Target is a specific cell-line
Relationship Type: N - Non-molecular target assigned
Confidence: Target assigned is non-molecular
Standard TypeActivity Comment
ActivityNon-Toxic
ActivityNon-Toxic
ActivityNon-Toxic
ActivityNon-Toxic
ActivityNon-Toxic
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Reverse transcriptase/RNaseH
External ID: CHEMBL1018093
Protocol: N/A
Comment: Journal: J Nat Prod
Year: 1991
Volume: 54
Issue: 1
First Page: 143
Last Page: 154
DOI: 10.1021/np50073a012

Target ChEMBL ID: CHEMBL247
ChEMBL Target Name: Human immunodeficiency virus type 1 reverse transcriptase
ChEMBL Target Type: SINGLE PROTEIN - Target is a single protein chain
Relationship Type: D - Direct protein target assigned
Confidence: Direct single protein target assigned
Standard TypeStandard RelationStandard ValueStandard UnitsData Validity Comment
IC50<150ug.mL-1Outside typical range
IC50>200ug.mL-1Outside typical range
IC50<50ug.mL-1
IC50<200ug.mL-1Outside typical range
IC50>200ug.mL-1Outside typical range
IC50>200ug.mL-1Outside typical range
IC50>200ug.mL-1Outside typical range
IC50=100ug.mL-1Outside typical range
IC50=71ug.mL-1Outside typical range
IC50>200ug.mL-1Outside typical range
IC50<200ug.mL-1Outside typical range
IC50<150ug.mL-1Outside typical range
IC50<150ug.mL-1Outside typical range
IC50=18ug.mL-1
IC50>200ug.mL-1Outside typical range
IC50=18ug.mL-1
IC50>200ug.mL-1Outside typical range
IC50<150ug.mL-1Outside typical range
IC50>200ug.mL-1Outside typical range
IC50>200ug.mL-1Outside typical range
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:glucocorticoid receptor [Homo sapiens]
External ID: GRA646
Protocol: Please refer to other AIDs 720691, 720687, 720685, 720678 and 720681, for detailed assay protocols.
Comment: This summary is written for the purposes of summarizing the compound activities from the project combining the results from both the GR agonist mode assay (AID 720691) and auto fluorescence counter screens (AIDs 720687, 720685, 720678 and 720681). For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Potency and efficacy were used for determining relative score. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 5 and 30 determined by phenotype.

Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Activity SummaryRatio ActivityRatio Potency (uM)Ratio Efficacy (%)530 nm Activity530 nm Potency (uM)530 nm Efficacy (%)460 nm Activity460 nm Potency (uM)460 nm Efficacy (%)Blue (460 nm) auto fluorescence outcomeSample Source
inconclusiveinconclusive0inactive0inactive0inactiveSigmaAldrich
inactiveinactive0inactive0inactive0inactiveSigmaAldrich
inactiveinactive0inactive0inactive0inactiveSigmaAldrich
inactiveinactive0inactive0inactive0inactiveSigmaAldrich
inconclusiveactive agonist26.2133798280.63773882active antagonist23.36269936-80.71273442active antagonist26.21337982-33.67998135inactiveSigmaAldrich
inactiveinactive0inactive0inactive0inactiveSigmaAldrich
inactiveinactive0inconclusive agonist0inconclusive agonist0inactiveSigmaAldrich
inconclusiveinconclusive agonist25.01773299170.756549active antagonist26.21337982-71.55109769inconclusive antagonist26.83246391-39.31724907inactiveSigmaAldrich
inactiveinactive0inactive0inactive0inactiveSigmaAldrich
inactiveinactive0inactive0inactive0inactiveSigmaAldrich
inactiveinactive0inactive0inactive0inactiveSigmaAldrich
inactiveinactive0inactive0inactive0inactiveSigmaAldrich
inactiveinactive0inactive0inactive0inactiveSigmaAldrich
inactiveinactive0inactive0inactive0inactiveSigmaAldrich
inactiveinactive0inactive0inactive0inactiveSigmaAldrich
inactiveinactive0inactive0inactive0inactiveSigmaAldrich
inactiveinactive0inactive0inactive0inactiveSigmaAldrich
inconclusiveactive agonist14.2449376949.76333982active antagonist13.44808836-78.84104162inconclusive antagonist13.44808836-40.31184202inactiveSigmaAldrich
inactiveinactive0inactive0inactive0inactiveSigmaAldrich
inactiveinactive0inactive0inactive0inactiveSigmaAldrich
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:quadruplex DNA
External ID: CHEMBL5105693
Protocol: N/A
Comment: Journal: Bioorg Med Chem Lett
Year: 2022
Volume: 73
First Page: 128886
Last Page: 128886
DOI: 10.1016/j.bmcl.2022.128886

Target ChEMBL ID: CHEMBL3832742
ChEMBL Target Name: quadruplex DNA
ChEMBL Target Type: NUCLEIC-ACID - Target is DNA, RNA or PNA
Relationship Type: M - Molecular target other than protein assigned
Confidence: Target assigned is molecular non-protein target
Standard TypeStandard RelationStandard ValueStandard Units
Delta Tm=-4degrees C
Delta Tm=-1.8degrees C
Delta Tm=-2.4degrees C
Delta Tm=-6.6degrees C
Delta Tm=-4.7degrees C
Delta Tm=-6.1degrees C
Delta Tm=-7.6degrees C
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ICCB-Longwood/NSRB Screening Facility, Harvard Medical School 靶标:ORF 73 [Human herpesvirus 8 type M]
External ID: HMS791
Protocol: Prior to screening, FITC LANA1-23 was stored lyophilized at -80 degC and freshly purified chicken nucleosomes were stored at 4 degC in 20 mM Tris pH 7.5, 600 mM NaCl, 0.2 mM EDTA, 0.5 mM B-Mercaptoethanol.

On the day of screening, FITC LANA1-23 was resuspended at 50 uM in TEN-BT buffer (10 mM Tris-HCl (pH 7.5), 1 mM EDTA (pH 8.0), 2.5 mM NaCl, 5 mM Beta-mercaptoethanol, 0.01% Triton-X-100) and diluted to a final concentration of 50 nM in TEN-BT buffer plus 240 nM of purified nucleosomes (480 nM LANA peptide binding sites). 30 uL per well were dispensed in column 1-22 in Corning #3575 black 384 well plates.

Wells in column 23 contained 30 uL of the same mixture (for pilot screen) or with the addition of 10 uM monensin (for HTS) as a negative control. In column 24, 1250 nM unlabeled WT LANA1-23 peptide (for pilot screen) or 10 uM mitoxantrone (for HTS) was added to the wells as a positive control. Compounds were transferred into wells via stainless steel pin array (100 nL) and the reaction was incubated at room temperature for 10 to 45 minutes (stable for up to 2 hours). Library plates were screened in duplicate, with both assay plates in a given set prepared on the same day.

Following a room temperature incubation of 10 to 45 minutes, the assay is read on a EnVision plate reader using a 480 nM excitation filter, 535 nM S and P emission filters and D505fp/D535 dichoric mirror. mP value for FP measurement = 1000*(S-G*P)/(S+G*P) where S= , P=, G= G-factor. The G Factor = 1.
Comment: LANA 1-23 peptide containing the first 23 amino acids of the LANA protein from Kaposi's sarcoma herpesvirus (KSHV) was synthesized with an N-terminal FITC via a beta alanine linker and HPLC purified (peptide sequence: [FITC]-Beta alanine-MAPPGMRLRSGRSTGAPLTRGSC-[NH2]).

Data analysis: Z-scores were calculated for each replicate well using the mean and standard deviation of plate experimental well FP values. Compounds were considered active if the Z-score for both replicates < -2. Wells with high total fluorescence intensity (high S and P channel values) were excluded from further consideration. Activity scores were calculated based on replicate average FP Z-scores. For wells with average Z-score >= 0, the activity score was set to 0. For wells with replicate average Z-score < 0, replicate Z-score was divided by 4 and multiplied by -100. The replicate average was then used to determine the well activity score. Values > 100 (replicate average Z-score < -4) were set to 100.
FP_AP Channel_AS Channel_AFP_BP Channel_BS Channel_BZ-score_AZ-score_B
91.890.20.1260.03
93.294.90.2610.457
94.892.90.4160.275
89.985.7-0.058-0.379
91.590.10.0970.021
88.789.6-0.174-0.025
92.588.20.194-0.152
91.791.60.1160.157
93.391.20.2710.121
90.586.60-0.297
87.188.8-0.329-0.097
87.685.8-0.28-0.37
89.287.4-0.126-0.224
87.286-0.319-0.351
85.886.1-0.454-0.342
8892-0.2420.193
95.497.70.4740.711
98.697.50.7840.693
9088.4-0.048-0.134
98.693.60.7840.338
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:N/A
External ID: MALG0567
Protocol: The 1536-well gametocycidal viability assay was based on the previous method of Tanaka et al. Stage III-V gametocytes were tested against three compound libraries, including 4265 compounds from NCGC pharmaceutical collection, 400 from Malaria Box library, and 550 from an internal collection of kinase inhibitors. Briefly, 2.5 ul/well incomplete medium was dispensed into each well of 1,536-well plates using the Multidrop Combi followed by 23 nl compound transferring using the NX-TR Pintool (WAKO Scientific Solutions, San Diego, CA). Then, 2.5 ul/well of gametocytes was dispensed with a seeding density of 20,000 cells/well using the Multidrop Combi. The assay plates were incubated for 72 h at 37C with 5% CO2. After addition of 5 ul/well of 2X AlamarBlue dye (Life Technologies, cat. no. DAL1100), the plates were incubated for 24 h at 37C with 5% CO2 and then were read in a fluorescence detection mode (Ex = 525 nm, Em = 598 nm) on a ViewLux plate reader (PerkinElmer).
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0003541572 uMActivity at 0.0007804147 uMActivity at 0.00128 uMActivity at 0.00234 uMActivity at 0.00384 uMActivity at 0.00702 uMActivity at 0.012 uMActivity at 0.021 uMActivity at 0.035 uMActivity at 0.063 uMActivity at 0.086 uMActivity at 0.182 uMActivity at 0.258 uMActivity at 0.417 uMActivity at 0.795 uMActivity at 1.685 uMActivity at 1.846 uMActivity at 4.638 uMActivity at 6.957 uMActivity at 10.66 uMActivity at 19.94 uMActivity at 31.13 uMActivity at 46.10 uMActivity at 93.93 uMActivity at 172.6 uMActivity at 231.0 uMCompound QC
Inhibitor0.0935154.693598Complete curve; high efficacy-7.02921.10.9814-146.09978.5938-1.10 0 0 0 0 0 0 0 0 0 0-149.38620.82076.86470.67910.9782-67.4006-102.1412-114.8055-133.0402-148.3233-149.2304-149.3862QC'd by "SigmaAldrich"
Inhibitor0.0469131.670797Complete curve; high efficacy-7.32920.70.9736-119.008512.6622-1.10 0 0 0 0 0 0 0 0 0 0-121.68564.93681.0179-2.144-47.6702-70.9047-78.6554-87.469-105.5788-116.3017-120.6225-121.6856QC'd by "Selleck"
Inhibitor0.006684.929296Complete curve; high efficacy-8.17921.24750.9877-84.92290.0063-1.10 0 0 0 0 0 0 0 0 0 0-77.5181-4.1745-21.34-41.4231-70.152-80.9864-85.8591-89.0178-86.9489-85.5856-83.0404-77.5181QC'd by "JohnsHopkins"
Inhibitor0.0118100.443395Complete curve; high efficacy-7.92921.17050.9878-84.899215.5441-1.10 0 0 0 0 0 0 0 0 0 0-90.70436.01479.5802-21.2099-53.734-69.8068-77.6527-79.6422-83.2532-88.1242-85.5758-90.7043QC'd by "Sequoia"
Inhibitor0.1663141.633695Complete curve; high efficacy-6.779210.9892-128.120413.5132-1.10 0 0 0 0 0 0 0 0 0 0-136.880711.867813.26622.2436-0.5908-17.7219-67.808-96.5304-112.4202-110.9171-129.8866-136.8807QC'd by "SigmaAldrich"
Inhibitor0.02790.554594Complete curve; high efficacy-7.5683.67720.999-89.81350.741-1.10 0 0 0 0 0 0 0 0 0 0-90.52050.756-0.846-5.0661-74.8914-87.6289-88.7218-88.3319-90.532-91.8339-90.0059-90.5205QC'd by "Tocris"
Inhibitor0.0662106.764594Complete curve; high efficacy-7.17921.46410.9837-103.23573.5288-1.10 0 0 0 0 0 0 0 0 0 0-116.25651.369-0.79760.2847-4.5164-54.339-80.5065-91.6482-99.3613-100.5238-104.506-116.2565QC'd by "NIEHS"
Inhibitor0.1177115.843894Complete curve; high efficacy-6.92921.34430.9819-117.1061-1.2623-1.10 0 0 0 0 0 0 0 0 0 14.4447-8.7321-5.1555-2.07771.9174-43.5671-78.2683-95.3251-115.0348-115.5958-124.31654.4447QC'd by "NIEHS"
Inhibitor0.1663128.528994Complete curve; high efficacy-6.77921.64360.9725-126.38822.1407-1.10 0 0 0 0 0 0 0 0 0 0-140.4313-2.80441.08562.28212.0499-14.3651-81.7532-101.0222-105.8782-121.507-138.7623-140.4313QC'd by "Labotest"
Inhibitor0.3034145.50894Complete curve; high efficacy-6.5182.35310.9645-139.58025.9278-1.10 0 0 0 0 0 0 0 0 0 0-164.98844.15414.02912.82374.3784-1.5742-93.6828-111.7838-118.1332-141.2241-150.3446-164.9884QC'd by "Vitas"
Inhibitor0.046988.34293Complete curve; high efficacy-7.32921.37230.9544-92.1654-3.8235-1.10 0 0 0 0 0 0 0 0 0 0-108.9426-13.2844-3.52390.2999-25.2059-64.7136-72.735-81.7312-84.6404-88.6351-94.7673-108.9426QC'd by "Microsource"
Inhibitor0.070832.349393Complete curve; high efficacy-7.150.40.9998-98.5263-130.8756-1.10 0 0 1-108.6376-109.4797-105.4246-102.5219-108.6376QC'd by "SigmaAldrich"
Inhibitor0.3722118.810292Complete curve; high efficacy-6.42921.10.9935-121.9435-3.1333-1.10 0 0 0 0 0 0 0 0 0 0-127.8234-11.3494-2.0872-2.6541-4.2104-15.8158-42.2192-78.7861-98.358-113.5802-117.5418-127.8234QC'd by "Selleck"
Inhibitor0.0743100.381492Complete curve; high efficacy-7.12921.46410.9876-89.042711.3387-1.10 0 0 0 0 0 0 0 0 0 0-93.33627.85819.74257.1857.3252-40.3237-66.2343-77.2974-84.8773-91.5077-92.181-93.3362QC'd by "SigmaAldrich"
Inhibitor0.1177102.295191Complete curve; high efficacy-6.92922.84730.9829-89.915512.3796-1.10 0 0 0 0 0 0 0 0 0 0-107.81236.963711.333312.195915.9836-1.5088-68.4419-83.4615-85.0976-87.4056-86.2068-107.8123QC'd by "Selleck"
Inhibitor0.046978.700691Complete curve; high efficacy-7.32923.51170.9854-79.7585-1.0579-1.10 0 0 0 0 0 1 0 0 0 0-89.8181-1.896-2.2203-0.0692-4.0216-61.5743-70.2002-2.1835-77.3305-78.9929-81.1936-89.8181QC'd by "Selleck"
Inhibitor0.3722123.853591Complete curve; high efficacy-6.42921.98870.9819-117.34696.5066-1.10 0 0 0 0 0 0 0 0 0 0-135.81822.82056.83845.11828.77272.6009-16.0727-85.914-98.5339-110.3252-113.4396-135.8182QC'd by "Toronto Research"
Inhibitor0.132193.841691Complete curve; high efficacy-6.87921.1110.9849-90.79593.0457-1.10 0 0 0 0 0 0 0 0 0 0-97.0042-5.34864.51841.4758-0.154-26.7948-59.3019-70.7041-80.6367-87.9767-91.0336-97.0042QC'd by "Prestwick Chemical; Inc."
Inhibitor0.316250.397691Complete curve; high efficacy-6.54.50450.9153-108.343-57.9454-1.10 0 0 0-104.8035-91.6212-110.7025-109.4596-104.8035QC'd by "SigmaAldrich"
Inhibitor0.083385.877291Complete curve; high efficacy-7.07922.18760.9957-84.49741.3799-1.10 0 0 0 0 0 0 0 0 0 0-80.2092-2.63883.18312.9768-5.1792-26.4406-72.7929-83.6942-88.0181-86.4306-84.6422-80.2092QC'd by "Sequoia"
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Macrophage migration inhibitory factor
External ID: CHEMBL5133028
Protocol: N/A
Comment: Journal: Bioorg Med Chem Lett
Year: 2022
Volume: 55
First Page: 128445
Last Page: 128445
DOI: 10.1016/j.bmcl.2021.128445

Target ChEMBL ID: CHEMBL2085
ChEMBL Target Name: Macrophage migration inhibitory factor
ChEMBL Target Type: SINGLE PROTEIN - Target is a single protein chain
Relationship Type: D - Direct protein target assigned
Confidence: Direct single protein target assigned
Standard TypeStandard RelationStandard Value
Ratio IC50=2.46
Ratio IC50=2.46
Ratio IC50=2.46
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:N/A
External ID: UCH01
Protocol: NCGC Assay Protocol Summary:

Human chordoma cell line UCH-1 was dispensed at 800 per well in 4uL of culture medium into white solid bottom 1536-well plates (Corning Life Sciences, Corning, NY) using a Multidrop Combi (Thermo Scientific, Waltham, MA) dispenser. The assay plates were incubated at 37 C and 5% CO2 for an overnight, and then 23nL of compounds dissolved in DMSO and positive control were transferred using a Pintool station (Wako, San Diego, CA). Compound treatment was followed by the addition of 1uL of the combination compounds (1uM Auranofin, 500nM each of Camptothecin, Doxorubicin, Rubitecan, and Topotecan) and assay medium to each well of the assay plates using Flying Reagent Dispenser (FRD, Aurora Discovery, San Diego, CA). The assay plates were incubated at 37 C and 5% CO2 for 48hr. Then 5uL of CellTiter-Glo reagent (Promega Corporation, Madison, WI) was added to each well of the assay plates using FRD. After 30min incubation at room temperature, the luminescence signal was quantified using a ViewLux plate reader (PerkinElmer, Shelton, CT).
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000589862 uMActivity at 0.0001318894 uMActivity at 0.0002736992 uMActivity at 0.0006007706 uMActivity at 0.00134 uMActivity at 0.00300 uMActivity at 0.00672 uMActivity at 0.015 uMActivity at 0.034 uMActivity at 0.075 uMActivity at 0.169 uMActivity at 0.376 uMActivity at 0.840 uMActivity at 1.878 uMActivity at 4.198 uMActivity at 9.215 uMActivity at 20.60 uMActivity at 46.08 uMCompound QC
Cytotoxic0.001831.423920Complete curve; partial efficacy; poor fit-8.753.06540.8263-32.4239-1-1.40 0 0 0 0 0 1 0 0 0 0 0 0 1 0-35.7899-5.26020.6718-5.8362-34.6763-38.4483-36.6565-12.9105-27.1061-24.3923-27.523-39.1032-25.5591-32.6986-51.5215-35.7899QC'd by Prestwick Chemical; Inc.
Inactive043.41580.52828.561510.0412-21.4572-9.91013.9892-1.6951-11.7215-8.1282-10.97640.590315.46433.4158QC'd by Prestwick Chemical; Inc.
Inactive0-5.451.69240.7916-3.435429.867640 0 0 0 0 1 0 0 0 0 0 0 0 1 0-2.325723.744826.948339.120329.968823.695812.632832.835924.413234.381529.86132.814215.857213.230734.167-2.3257QC'd by Prestwick Chemical; Inc.
Inactive04-25.4391-15.0204-2.9795-11.6274-17.8791-18.7342-16.0568-18.5681-8.6261-0.4337-9.469-17.2541-19.0618-20.2765-20.1196-25.4391QC'd by Tocris
Inactive04-15.5946-12.6983.3906-3.845-10.7092-8.9128-3.879-9.2601-1.8973-0.752-6.498-14.6631-3.8808-12.5709-9.8904-15.5946QC'd by Tocris
Cytotoxic0.199560.864766Complete curve; partial efficacy-6.70.70.9894-52.96837.8964-1.21 0 0 0 0 0 0 0 0 0 0 0 0 0 0-52.9766-11.7559.09574.709-0.0964-2.7993-4.8257-12.9121-18.2406-28.232-37.1333-47.5945-45.5767-48.7112-47.2288-52.9766QC'd by Tocris
Inactive03.06540.7234-14.2314-0.540 1 0 0 0 0 0 0 0 0 0 1 0 0 0-15.0260.158814.34-3.5174-6.55531.66942.6283-6.4334.41334.297-9.6244-9.62912.763-16.8595-12.9766-15.026QC'd by Tocris
Inactive03.06540.4866-2.832241 1 0 0 0 0 0 0 0 0 0 0 0 0 1-3.22193.1394-11.24260.9841-8.19351.8313-4.0854-3.5011-1.2791-7.75536.11421.03847.41512.60270.6725-3.2219QC'd by Vitas
Inactive04-20.3775-14.2412-0.05380.3603-5.5260.6783-7.7262-9.1303-3.86456.8524-7.1354-3.3754-13.4261-12.4808-5.7308-20.3775QC'd by InterBioScreen
Inactive0-7.70.40.5209-15.840722.29441 1 0 0 0 0 0 0 0 0 0 0 0 0 0-25.4939-9.421224.078911.00615.558415.3461-13.88140.0662-2.3176-0.2033-18.9833-12.7455-5.4708-9.987-4.4152-25.4939QC'd by NCI
Inactive0-7.950.70.357212.54945.881740 0 0 0 0 0 0 0 1 0 0 0 0 1 010.468615.123159.454343.44341.73278.474618.368627.507419.207539.69268.599826.584915.37711.259640.043810.4686QC'd by NCI
Inactive04-8.27485.5659-23.64215.77960.4421-10.3839-11.3824-6.339811.2546-11.0345-12.1961-6.4315-2.34728.16624.7643-8.2748QC'd by NCI
Inactive04-1.414610.783641.63319.435719.07262.4819-2.490934.81020.443918.667522.023734.2910.672827.79514.6731-1.4146QC'd by NCI
Inactive0424.517424.524747.128831.917832.143718.609418.51528.6672.163833.35526.756748.31323.406535.215419.732524.5174QC'd by NCI
Cytotoxic25.1189105.563120Single point of activity-4.61.34430.7555-83.262822.3004-30 0 0 0 0 0 1 0 1 0 0 0 0 0 0-61.680218.596547.102225.571527.193214.486120.217562.9194.346756.834719.771727.31612.0298-8.9488-0.1149-61.6802QC'd by NCI
Cytotoxic11.220262.573220Single point of activity-4.950.20.4464-49.227813.3454-30 1 0 1 0 0 0 0 0 0 0 0 0 0 0-37.12925.338150.492114.5977-33.03260.0708-8.1047-8.7784-16.045-12.5026-14.30073.6764-0.7727-22.7169-8.7229-37.1292QC'd by NCI
Inactive045.583920.9173-0.876420.3507-6.09256.9648-1.98674.3646-24.7642-13.974417.42878.9822-1.15145.79615.86025.5839QC'd by NCI
Inactive04-7.11544.44263.4244-7.4615-3.24612.881913.18722.651513.80112.90682.7103-2.00389.31571.89620.2248-7.1154QC'd by NCI
Inactive0-6.83.51170.471314.6956-3.384841 0 1 0 0 0 0 0 0 0 0 0 0 0 1-5.471612.43677.87234.8116-13.30797.3422-18.69013.10113.621423.089124.78795.43410.527716.36438.9052-5.4716QC'd by NCI
Cytotoxic5.011947.711920Partial curve; partial efficacy; poor fit-5.30.20.5381-51.5537-3.8419-2.40 0 0 0 0 0 0 0 0 0 1 0 0 0 0-27.7038-12.3767-22.4879-1.9516-20.3869-7.5685-20.4878-16.1251-17.5633-7.923-24.46534.0747-33.453-33.2258-39.6281-27.7038QC'd by NCI
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Macrophage migration inhibitory factor
External ID: CHEMBL5133029
Protocol: N/A
Comment: Journal: Bioorg Med Chem Lett
Year: 2022
Volume: 55
First Page: 128445
Last Page: 128445
DOI: 10.1016/j.bmcl.2021.128445

Target ChEMBL ID: CHEMBL2085
ChEMBL Target Name: Macrophage migration inhibitory factor
ChEMBL Target Type: SINGLE PROTEIN - Target is a single protein chain
Relationship Type: D - Direct protein target assigned
Confidence: Direct single protein target assigned
Standard TypeStandard RelationStandard ValueStandard UnitsActivity Comment
Inhibition=61%
Inhibition%NA
Inhibition=45%
Inhibition=15%
Inhibition=15%
Inhibition=61%
Inhibition=61%
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Macrophage migration inhibitory factor
External ID: CHEMBL5133030
Protocol: N/A
Comment: Journal: Bioorg Med Chem Lett
Year: 2022
Volume: 55
First Page: 128445
Last Page: 128445
DOI: 10.1016/j.bmcl.2021.128445

Target ChEMBL ID: CHEMBL2085
ChEMBL Target Name: Macrophage migration inhibitory factor
ChEMBL Target Type: SINGLE PROTEIN - Target is a single protein chain
Relationship Type: D - Direct protein target assigned
Confidence: Direct single protein target assigned
PubChem Standard ValueStandard TypeStandard RelationStandard ValueStandard UnitsData Validity Comment
255IC50=255000nMOutside typical range
65.3IC50=65300nM
211IC50=211000nMOutside typical range
160IC50=160000nMOutside typical range
400IC50>400000nMOutside typical range
98.1IC50=98100nM
85.4IC50=85400nM